{"content":"<li class=\"n-box-item date-title\" data-end=\"1516251599\" data-start=\"1516165200\" data-txt=\"Monday, December 23, 2019\">Wednesday, January 17, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3323429\" data-ts=\"1516232824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AES\" target=\"_blank\">AES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323429-aes-pops-valueact-takes-stake-pledges-clean-energy-push\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AES pops as ValueAct takes stake, pledges clean energy push</a></h4><ul>     <li>AES Corp. (NYSE:<a href='https://seekingalpha.com/symbol/AES' title='The AES Corporation'>AES</a>)&nbsp;<font color='green'>+4.6%</font> after-hours following news that ValueAct Capital Management has <a href=\"https://www.bloomberg.com/news/articles/2018-01-17/activist-valueact-takes-aes-stake-in-push-for-cleaner-energy\" target=\"_blank\">taken an active stake</a> in the power generator.</li>     <li>AES says ValueAct founder Jeffrey Ubben will join its board to help push for cleaner energy resources and will work with the company on its plan to sell coal assets, reduce debt and develop more solar power and battery storage.</li>     <li>As of November, ~37% of AES&rsquo;s power production still came from coal, and the company has set a goal of reducing the figure to 33% by the end of 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323429\" data-linked=\"AES pops as ValueAct takes stake, pledges clean energy push\" data-tweet=\"$AES - AES pops as ValueAct takes stake, pledges clean energy push https://seekingalpha.com/news/3323429-aes-pops-valueact-takes-stake-pledges-clean-energy-push?source=tweet\" data-url=\"https://seekingalpha.com/news/3323429-aes-pops-valueact-takes-stake-pledges-clean-energy-push\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323427\" data-ts=\"1516231176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARWR\" target=\"_blank\">ARWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323427-bloomberg-arrowhead-offering-40m-up-to-12_6-discount\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Arrowhead offering at $40M, up to 12.6% discount</a></h4><ul>   <li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a>) is <font color='red'>off 10%</font> after hours on word that its <a href=\"https://seekingalpha.com/news/3323369-arrowhead-readies-equity-offering-shares-7-percent-hours\" target=\"_blank\">equity offering</a> will come at $5.00-$5.25/share, an 8.2%-12.6% discount vs. today's close of $5.72.</li>    <li>Shares are quoted at $5.15 after hours at the moment.</li>    <li>The offering will come in at $40M, Bloomberg reports. Shares will come via Jefferies, Barclays, and Cantor Fitzgerald.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323427\" data-linked=\"Bloomberg: Arrowhead offering at $40M, up to 12.6% discount\" data-tweet=\"$ARWR - Bloomberg: Arrowhead offering at $40M, up to 12.6% discount https://seekingalpha.com/news/3323427-bloomberg-arrowhead-offering-40m-up-to-12_6-discount?source=tweet\" data-url=\"https://seekingalpha.com/news/3323427-bloomberg-arrowhead-offering-40m-up-to-12_6-discount\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323421\" data-ts=\"1516228728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323421-after-hours-gainers-losers-1-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (1/17/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/ESIO' title='Electro Scientific Industries, Inc.'>ESIO</a> <font color='green'>+22.9%</font>. <a href='https://seekingalpha.com/symbol/PTC' title='PTC Inc.'>PTC</a> <font color='green'>+7.1%</font>. <a href='https://seekingalpha.com/symbol/AES' title='The AES Corporation'>AES</a> <font color='green'>+4.7%</font>. <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a> <font color='green'>+2.9%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='red'>-9.8%</font>. <a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='red'>-8.4%</font>. <a href='https://seekingalpha.com/symbol/PLXS' title='Plexus Corp.'>PLXS</a> <font color='red'>-6.8%</font>. <a href='https://seekingalpha.com/symbol/SLM' title='SLM Corporation'>SLM</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties'>IIPR</a> <font color='red'>-4.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323421\" data-linked=\"After Hours Gainers / Losers (1/17/2018)\" data-tweet=\"$ESIO $PTC $AES - After Hours Gainers / Losers (1/17/2018) https://seekingalpha.com/news/3323421-after-hours-gainers-losers-1-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323421-after-hours-gainers-losers-1-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323420\" data-ts=\"1516228512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESIO\" target=\"_blank\">ESIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323420-esi-reports-strong-preliminary-q3-results-sharesplus-22-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ESI reports strong preliminary Q3 results; shares +22% AH</a></h4><ul>     <li>Electro Scientific Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/ESIO' title='Electro Scientific Industries, Inc.'>ESIO</a>) now expects Q3 revenue in the range of $106M - $111M vs. a consensus of $85M.</li>     <li>The company now expects adj. EPS above the <a href=\"https://seekingalpha.com/news/3307407-electro-scientific-fiscal-q2-beat-propels-shares-33-percent-premarket\" target=\"_blank\">guided range provided on Nov. 1</a> vs. a consensus of $0.55.</li>     <li>The company also expects to report Q3 bookings of ~$134M (+204% Y/Y).</li>     <li>CEO Michael Burger: &ldquo;Given the strong third quarter demand, our currently elevated backlog position and our visibility into the current buy cycle, we now expect fourth quarter 2018 and first quarter 2019 revenues to approximate the same level as the third quarter.&rdquo;</li>     <li>The company anticipates reporting its Q3 results on Jan. 31.</li>     <li>Shares&nbsp;<font color='green'>+22% AH</font></li>     <li><a href=\"https://seekingalpha.com/pr/17049519-esi-reports-strong-preliminary-third-quarter-2018-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3323420\" data-linked=\"ESI reports strong preliminary Q3 results; shares +22% AH\" data-tweet=\"$ESIO - ESI reports strong preliminary Q3 results; shares +22% AH https://seekingalpha.com/news/3323420-esi-reports-strong-preliminary-q3-results-sharesplus-22-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3323420-esi-reports-strong-preliminary-q3-results-sharesplus-22-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323412\" data-ts=\"1516226415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323412-bloomberg-apple-employees-will-get-2500-bonus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Apple employees will get $2,500 bonus</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) will issue employee bonuses of $2,500 worth of restricted stock units, according to <a href=\"https://www.bloomberg.com/technology\" target=\"_blank\">Bloomberg</a> sources. The bonuses come as the company plans to repatriate most of its overseas cash. &nbsp;</li><li>           Employees below the senior-level director position will be eligible. Apple has over 120K employees including its retail store workers. </li><li> Apple closed today&nbsp;<font color='green'>up 1.7%</font>.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3323324-apple-plans-add-350b-us-economy-38b-repatriated-tax-payments\" target=\"_blank\">Apple plans to add $350B to US economy, $38B in repatriated tax payments</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323412\" data-linked=\"Bloomberg: Apple employees will get $2,500 bonus\" data-tweet=\"$AAPL - Bloomberg: Apple employees will get $2,500 bonus https://seekingalpha.com/news/3323412-bloomberg-apple-employees-will-get-2500-bonus?source=tweet\" data-url=\"https://seekingalpha.com/news/3323412-bloomberg-apple-employees-will-get-2500-bonus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>121&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323409\" data-ts=\"1516225735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLXS\" target=\"_blank\">PLXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323409-plexusminus-6_8-after-q1-misses-mixed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plexus -6.8% after Q1 misses, mixed guidance</a></h4><ul><li>        Plexus (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXS' title='Plexus Corp.'>PLXS</a>) shares are&nbsp;<font color='red'>down 6.8%</font>&nbsp;aftermarket following Q1 results that missed EPS and revenue estimates. Mixed Q2 guidance has revenue from $670M to $710M (consensus: $693.60M) and EPS from $0.68 to $0.78 (consensus: $0.82).</li><li>               Sector performance: Healthcare/Life Sciences, $237M (+12% Y/Y); Industrial/Commercial, $207M (+0.5%); Communications, $133M (+1.5%); Aerospace/Defense, $100M (+15%).&nbsp;</li><li>               Financials: ROIC, 16.2%; FCF, $52.4M; cash and equivalents, $506.7M.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17049561-plexus-announces-fiscal-first-quarter-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323386-plexus-misses-0_05-misses-revenue\" target=\"_blank\">Plexus misses by $0.05, misses on revenue</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323409\" data-linked=\"Plexus -6.8% after Q1 misses, mixed guidance\" data-tweet=\"$PLXS - Plexus -6.8% after Q1 misses, mixed guidance https://seekingalpha.com/news/3323409-plexusminus-6_8-after-q1-misses-mixed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3323409-plexusminus-6_8-after-q1-misses-mixed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323406\" data-ts=\"1516224866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AA\" target=\"_blank\">AA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323406-alcoaminus-5-q4-earnings-come-up-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcoa -5% as Q4 earnings come up short</a></h4><ul>     <li>Alcoa (<a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='green'>+1.3%</font>) <font color='red'>-4.9%</font> after-hours as <a href=\"https://seekingalpha.com/news/3323378-alcoa-misses-0_18-misses-revenue\" target=\"_blank\">Q4 earnings</a> and revenues, which rose 25% from the year-ago quarter to $3.17B, miss Wall Street expectations.</li>     <li>AA reports Q4 EBITDA of $775M, up 38% Q/Q, on higher alumina pricing, but company guidance was for greater than $800M; for FY 2018, the company projects EBITDA at $2.6B-$2.8B.</li>     <li>For 2018, AA projects balanced global bauxite and alumina markets and a global aluminum deficit of 300K-700K metric tons, and sees 2018 global aluminum demand growth of 4.25%-5.25%, following the company's final 2017 global demand growth rate of 5.25%.</li>     <li>AA also announces changes to its U.S. and Canada defined benefit pension plans which it expects to both reduce its net pension and other post-employment benefits liability by $35M and record ~$20M in non-cash non-operating income in Q1 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323406\" data-linked=\"Alcoa -5% as Q4 earnings come up short\" data-tweet=\"$AA - Alcoa -5% as Q4 earnings come up short https://seekingalpha.com/news/3323406-alcoaminus-5-q4-earnings-come-up-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3323406-alcoaminus-5-q4-earnings-come-up-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323398\" data-ts=\"1516224635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTC\" target=\"_blank\">PTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323398-ptcplus-5_7-after-q1-beats-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC +5.7% after Q1 beats, in-line guidance</a></h4><ul><li>        PTC (NASDAQ:<a href='https://seekingalpha.com/symbol/PTC' title='PTC Inc.'>PTC</a>) shares are&nbsp;<font color='green'>up 5.7%</font>&nbsp;aftermarket following Q1 results that beat EPS and revenue estimates. In-line Q2 guidance has revenue from $300M to $305M (consensus: $302.53M) and EPS from $0.28 to $0.32 (consensus: $0.32).</li><li>                  In-line FY18 guidance has revenue from $1.235B to $1.25B (consensus: $1.23B) with EPS from $1.29 to $1.39 (consensus: $1.36).    </li><li>               Key metrics: Software revenue, $265M (+10% Y/Y); license and subscription bookings, $104M; subscription mix, 67%; total deferred revenue (billed and unbilled), $1.17B (+42%); subscription Annualized Recurring Revenue, $402M (+84%).&nbsp;</li><li>               More financials: Non-GAAP operating expenses, $183M (+$13M Y/Y); operating margin, 17% (+2 percentage points); operating cash flow, $25M; FCF, $19M; cash and equivalents, $342M; total debt, $743M.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17049491-ptc-announces-first-quarter-fiscal-year-2018-results\" target=\"_blank\">Press release</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323366-ptc-beats-0_01-beats-revenue\" target=\"_blank\">PTC beats by $0.01, beats on revenue</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323398\" data-linked=\"PTC +5.7% after Q1 beats, in-line guidance\" data-tweet=\"$PTC - PTC +5.7% after Q1 beats, in-line guidance https://seekingalpha.com/news/3323398-ptcplus-5_7-after-q1-beats-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3323398-ptcplus-5_7-after-q1-beats-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323388\" data-ts=\"1516224072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323388-paratek-pharma-readies-50m-stock-offering-shares-off-10-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paratek Pharma readies $50M stock offering; shares off 10% after hours</a></h4><ul><li>Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) <a href=\"https://seekingalpha.com/pr/17049524-paratek-announces-public-offering-common-stock\" target=\"_blank\">initiates </a>a $50M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>10%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323388\" data-linked=\"Paratek Pharma readies $50M stock offering; shares off 10% after hours\" data-tweet=\"$PRTK - Paratek Pharma readies $50M stock offering; shares off 10% after hours https://seekingalpha.com/news/3323388-paratek-pharma-readies-50m-stock-offering-shares-off-10-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3323388-paratek-pharma-readies-50m-stock-offering-shares-off-10-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323379\" data-ts=\"1516223628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323379-amicus-launches-galafold-in-spain-shares-up-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus launches Galafold in Spain; shares up 5% after hours</a></h4><ul><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) commences the <a href=\"https://seekingalpha.com/pr/17049488-amicus-therapeutics-launches-galafold-migalastat-treatment-fabry-disease-spain\" target=\"_blank\">commercial launch</a> of Galafold (migalastat) for the treatment of Fabry disease in Spain.</li><li>CEO John Crowley says, \"The commercial launch of Galafold in&nbsp;Spain&nbsp;adds to the tremendous momentum in expanding our launch throughout the EU, where we have now secured reimbursement in all five countries that have the largest Fabry populations within the EU. We believe that our pricing and reimbursement success throughout the EU, in addition to our global progress in securing additional approvals and completing new regulatory submissions, are a testament to the significant value of migalastat as the first oral precision medicine for people living with Fabry disease who have an amenable mutation.&rdquo;</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323379\" data-linked=\"Amicus launches Galafold in Spain; shares up 5% after hours\" data-tweet=\"$FOLD - Amicus launches Galafold in Spain; shares up 5% after hours https://seekingalpha.com/news/3323379-amicus-launches-galafold-in-spain-shares-up-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3323379-amicus-launches-galafold-in-spain-shares-up-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323376\" data-ts=\"1516223377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPGN\" target=\"_blank\">OPGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323376-opgen-reverse-splits-shares-1-25-shares-down-9-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OpGen reverse splits shares 1:25; shares down 9% after hours</a></h4><ul><li>Aimed at regaining Nasday's listing requirement of a minimum $1 bid price, OpGen (NASDAQ:<a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a>) <a href=\"https://seekingalpha.com/pr/17049486-opgen-announces-execution-reverse-stock-split\" target=\"_blank\">executes </a>a 1:25 reverse split of its common shares effective today. Post-split trading commences tomorrow.</li><li>Shares are down<font color='red'> 9%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323376\" data-linked=\"OpGen reverse splits shares 1:25; shares down 9% after hours\" data-tweet=\"$OPGN - OpGen reverse splits shares 1:25; shares down 9% after hours https://seekingalpha.com/news/3323376-opgen-reverse-splits-shares-1-25-shares-down-9-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3323376-opgen-reverse-splits-shares-1-25-shares-down-9-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323374\" data-ts=\"1516223309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMI\" target=\"_blank\">KMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323374-kinder-morgan-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kinder Morgan beats by $0.03, beats on revenue</a></h4><ul><li>Kinder Morgan (NYSE:<a href='https://seekingalpha.com/symbol/KMI' title='Kinder Morgan, Inc.'>KMI</a>): Q4 EPS of $0.21 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $3.63B (+7.1% Y/Y) <font color='green'>beats by $130M</font>.</li><li>Shares <font color='green'>+1.4%</font>.</li><li><a href='https://seekingalpha.com/pr/17049520-kinder-morgan-declares-dividend-0_125-fourth-quarter-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3323374\" data-linked=\"Kinder Morgan beats by $0.03, beats on revenue\" data-tweet=\"$KMI - Kinder Morgan beats by $0.03, beats on revenue https://seekingalpha.com/news/3323374-kinder-morgan-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3323374-kinder-morgan-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323369\" data-ts=\"1516223194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARWR\" target=\"_blank\">ARWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323369-arrowhead-readies-equity-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arrowhead readies equity offering; shares down 7% after hours</a></h4><ul><li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a>) is down&nbsp;<font color='red'>7%</font>&nbsp;after hours in response to its announced <a href=\"https://seekingalpha.com/pr/17049490-arrowhead-pharmaceuticals-announces-proposed-underwritten-offering-common-stock\" target=\"_blank\">stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323369\" data-linked=\"Arrowhead readies equity offering; shares down 7% after hours\" data-tweet=\"$ARWR - Arrowhead readies equity offering; shares down 7% after hours https://seekingalpha.com/news/3323369-arrowhead-readies-equity-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3323369-arrowhead-readies-equity-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323361\" data-ts=\"1516222273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DSX\" target=\"_blank\">DSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323361-j-p-morgan-downgrades-diana-shipping-navios-maritime-partners\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.P. Morgan downgrades Diana Shipping, Navios Maritime Partners</a></h4><ul>     <li>Diana Shipping (<a href='https://seekingalpha.com/symbol/DSX' title='Diana Shipping, Inc.'>DSX</a> <font color='red'>-5.7%</font>) and Navios Maritime Partners (<a href='https://seekingalpha.com/symbol/NMM' title='Navios Maritime Partners L.P.'>NMM</a> <font color='red'>-2.6%</font>) are lower after J.P. Morgan <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11041326/jpmorgan-turns-selective-on-dry-bulk-carriers-downgrade\" target=\"_blank\">downgrades</a> shares of both dry bulk carriers to Neutral from Overweight ahead of a cycle peak the firm expects later this year or in early 2019.</li>     <li>The firm says DSX's low risk profile limits upside potential vs. more spot-oriented companies, and it is concerned about the company's economic exposure to container shipping through its loans to Diana Containerships (<a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+3%</font>).</li>     <li>JPM says its NMM downgrade is based primarily on valuation, as the company enjoys positives such as low leverage, relatively higher charter coverage, low cost basis and diversification into the containership sector through long-term charters.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323361\" data-linked=\"J.P. Morgan downgrades Diana Shipping, Navios Maritime Partners\" data-tweet=\"$DSX $DSX $NMM - J.P. Morgan downgrades Diana Shipping, Navios Maritime Partners https://seekingalpha.com/news/3323361-j-p-morgan-downgrades-diana-shipping-navios-maritime-partners?source=tweet\" data-url=\"https://seekingalpha.com/news/3323361-j-p-morgan-downgrades-diana-shipping-navios-maritime-partners\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323360\" data-ts=\"1516221771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YY\" target=\"_blank\">YY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323360-nomura-boosts-yy-adrs-to-buy-shares-session-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura boosts YY ADRs to Buy; shares at session high</a></h4><ul>   <li>ADRs in <a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a> have moved up to a session high, <font color='green'>up 3.4%</font>, after an upgrade to Buy from Neutral at Nomura.</li>    <li>The firm has raised its price target to $161 from $80, implying 18.7% upside from the current price.</li>    <li>The ADRs have doubled over the past six months and <font color='green'>risen 214%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323360\" data-linked=\"Nomura boosts YY ADRs to Buy; shares at session high\" data-tweet=\"$YY - Nomura boosts YY ADRs to Buy; shares at session high https://seekingalpha.com/news/3323360-nomura-boosts-yy-adrs-to-buy-shares-session-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3323360-nomura-boosts-yy-adrs-to-buy-shares-session-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323357\" data-ts=\"1516221255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323357-google-clips-passes-fcc-release-coming-soon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Google Clips passes FCC, release coming soon?</a></h4><ul><li>        Google&rsquo;s (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) Clips camera received FCC certification this week and could release soon, according to <a href=\"http://variety.com/2018/digital/news/google-clips-fcc-release-1202667000/\" target=\"_blank\">Variety</a>.</li><li>               Google announced the $249 camera at the October launch event. The always-on camera uses AI to automatically shoot short videos and still pictures of moments the user would find interesting.&nbsp;</li><li>               The FCC filing lists the model number &ldquo;G015A,&rdquo; which has popped up on promo images of the device.&nbsp;</li><li>               GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) shares&nbsp;<font color='red'>dropped 0.6%</font>&nbsp;on the news even though Clips isn&rsquo;t an action camera. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299331-google-pixel-2-launch-event-live-updates\" target=\"_blank\">Google Pixel 2 launch event: Live updates</a> (Oct. 4, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299370-gopro-shares-google-launch-event\" target=\"_blank\">GoPro shares down after Google launch event</a> (Oct. 4, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299817-gopro-jpmorgan-dismisses-clips-concerns\" target=\"_blank\">GoPro up after JPMorgan dismisses Clips concerns</a> (Oct. 6, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323357\" data-linked=\"Google Clips passes FCC, release coming soon?\" data-tweet=\"$GOOG $GOOG $GOOGL - Google Clips passes FCC, release coming soon? https://seekingalpha.com/news/3323357-google-clips-passes-fcc-release-coming-soon?source=tweet\" data-url=\"https://seekingalpha.com/news/3323357-google-clips-passes-fcc-release-coming-soon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323353\" data-ts=\"1516220280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323353-dow-rides-boeings-dizzying-rise-to-300-pont-gain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dow rides Boeing&#39;s dizzying rise to 300-pont gain</a></h4><ul>     <li>The Dow surges more than 300 points toward its best single session rise in about seven weeks, boosted by another big gain in Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+3.6%</font>), which has <a href=\"https://blogs.wsj.com/moneybeat/2018/01/16/dow-rides-higher-on-boeing-once-again/\" target=\"_blank\">contributed about a third of the Dow&rsquo;s rise</a> from its first close above 25,000 on Jan. 4, by far the most points of any index constituent.</li>     <li>Boeing also continues to climb faster than any other stock in the index, up another 17% YTD after rising 89% last year.</li>     <li>Analysts are jumping on the bandwagon, with B. Riley <a href=\"https://www.barrons.com/articles/boeing-you-aint-seen-nothing-yet-1516133787\" target=\"_blank\">raising its BA stock price target to $433</a> from $380 as it expects a solid Q4 report and 2018 guidance as well as free cash flow rising with a reduced tax rate, to as high as $26/share in 2020, helping push the shares to new all-time highs; analysts at Baird, Citi and elsewhere also have <a href=\"https://seekingalpha.com/news/3322900-baird-citi-raise-pt-boeing\" target=\"_blank\">raised price targets</a>.</li>     <li>The stock's rise continued virtually uninterrupted today despite a report that Brazil regulators will <a href=\"https://www.streetinsider.com/Hot+M+and+A/Brazil+is+Said+to+Oppose+Embraer+%28ERJ%29+Split+for+Sale+to+Boeing+%28BA%29+-+Bloomberg/13693756.html\" target=\"_blank\">come out against</a> BA's potential takeover of Embraer (<a href='https://seekingalpha.com/symbol/ERJ' title='Embraer S.A.'>ERJ</a> <font color='red'>-0.2%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/DIA' title='SPDR Dow Jones Industrial Average ETF'>DIA</a>, <a href='https://seekingalpha.com/symbol/UDOW' title='ProShares UltraPro Dow 30 ETF'>UDOW</a>, <a href='https://seekingalpha.com/symbol/DOG' title='ProShares Short Dow 30 ETF'>DOG</a>, <a href='https://seekingalpha.com/symbol/DXD' title='ProShares UltraShort Dow30 ETF'>DXD</a>, <a href='https://seekingalpha.com/symbol/SDOW' title='ProShares UltraPro Short Dow 30 ETF'>SDOW</a>, <a href='https://seekingalpha.com/symbol/DDM' title='ProShares Ultra Dow 30 ETF'>DDM</a>, <a href='https://seekingalpha.com/symbol/UDPIX' title='ProFunds Ultra Dow 30 ProFund Inv'>UDPIX</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3323353\" data-linked=\"Dow rides Boeing&#39;s dizzying rise to 300-pont gain\" data-tweet=\"$BA $BA $ERJ - Dow rides Boeing&#39;s dizzying rise to 300-pont gain https://seekingalpha.com/news/3323353-dow-rides-boeings-dizzying-rise-to-300-pont-gain?source=tweet\" data-url=\"https://seekingalpha.com/news/3323353-dow-rides-boeings-dizzying-rise-to-300-pont-gain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323351\" data-ts=\"1516220076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323351-unitedhealths-q4-beat-buoys-peers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealth&#39;s Q4 beat buoys peers</a></h4><ul><li>UnitedHealth Group's (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+2.2%</font>) Q4 results, reported yesterday, have stoked buying the managed care/health insurance space.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+3.1%</font>)(<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+1.9%</font>)(<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+2.7%</font>)(<a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color='green'>+0.6%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='green'>+2.8%</font>)(<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a> <font color='green'>+2.8%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322795-unitedhealth-group-beats-0_07-beats-revenue\" target=\"_blank\">UnitedHealth Group beats by $0.07, beats on revenue</a> (Jan. 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322803-unitedhealth-group-q4-revenues-10-percent-non-gaap-eps-23-percent-updates-2018-guidance\" target=\"_blank\">UnitedHealth Group Q4 revenues up 10%; non-GAAP EPS up 23%; updates 2018 guidance</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323351\" data-linked=\"UnitedHealth&#39;s Q4 beat buoys peers\" data-tweet=\"$UNH $UNH $AET - UnitedHealth&#39;s Q4 beat buoys peers https://seekingalpha.com/news/3323351-unitedhealths-q4-beat-buoys-peers?source=tweet\" data-url=\"https://seekingalpha.com/news/3323351-unitedhealths-q4-beat-buoys-peers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323349\" data-ts=\"1516219873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323349-broadcom-calls-ftc-probe-immaterial-shares-resume-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcom calls FTC probe &#39;immaterial&#39;; shares resume gains</a></h4><ul>   <li>After a quick slide earlier this afternoon following the report of an <a href=\"https://seekingalpha.com/news/3323323-broadcom-goes-red-word-ftc-competition-investigation\" target=\"_blank\">FTC investigation</a>, Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>) has reclaimed positive territory, now <font color='green'>up 1%</font>.</li>    <li>Broadcom has confirmed the probe and says it's \"immaterial\" to its business and won't have an impact on the company's pending acquisition of Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>).</li>    <li>As noted, the probe has been ongoing but doesn't concern the company's wireless segment.</li>    <li>Shares are almost back to their session high of $266.53; they had dipped as low as $260.46 (<font color='red'>down 1.1%</font>) after the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323349\" data-linked=\"Broadcom calls FTC probe &#39;immaterial&#39;; shares resume gains\" data-tweet=\"$AVGO $AVGO $QCOM - Broadcom calls FTC probe &#39;immaterial&#39;; shares resume gains https://seekingalpha.com/news/3323349-broadcom-calls-ftc-probe-immaterial-shares-resume-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3323349-broadcom-calls-ftc-probe-immaterial-shares-resume-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323347\" data-ts=\"1516219666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDTI\" target=\"_blank\">IDTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323347-barclays-upgrades-integrated-device-technology-on-tailwinds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays upgrades Integrated Device Technology on tailwinds</a></h4><ul><li>        Barclays <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20180117130722IDTI\" target=\"_blank\">upgrades</a> Integrated Device Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/IDTI' title='Integrated Device Technology, Inc.'>IDTI</a>) from Underweight to Equal Weight and raises the price target from $28 to $33, which is 4% higher than yesterday&rsquo;s close.</li><li>               Firm sees a strong year ahead for memory interface with improving unit and higher DRAM loading tailwinds.&nbsp;</li><li>               Barclays isn&rsquo;t in love with wireless charging but with Apple&rsquo;s support, the firm does see a tailwind in Android.&nbsp;</li><li>               Integrated Device Technology shares are&nbsp;<font color='green'>up 2.9%</font>&nbsp;to $32.66. &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3323347\" data-linked=\"Barclays upgrades Integrated Device Technology on tailwinds\" data-tweet=\"$IDTI - Barclays upgrades Integrated Device Technology on tailwinds https://seekingalpha.com/news/3323347-barclays-upgrades-integrated-device-technology-on-tailwinds?source=tweet\" data-url=\"https://seekingalpha.com/news/3323347-barclays-upgrades-integrated-device-technology-on-tailwinds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323345\" data-ts=\"1516218964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323345-technology-top-gainers-losers-of-2_55-pm-1-17-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (1/17/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/PCOM' title='Points International, Ltd.'>PCOM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CTRL' title='Control4 Corporation'>CTRL</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HIVE' title='Aerohive Networks, Inc.'>HIVE</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ATEN' title='A10 Networks, Inc.'>ATEN</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323345\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (1/17/18)\" data-tweet=\"$ICHR $MOMO $PSTG - Technology - Top Gainers / Losers as of 2.55 pm (1/17/18) https://seekingalpha.com/news/3323345-technology-top-gainers-losers-of-2_55-pm-1-17-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3323345-technology-top-gainers-losers-of-2_55-pm-1-17-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323343\" data-ts=\"1516218238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323343-wsj-shari-redstone-looks-for-new-cbs-directors-in-viacom-re-merger-push\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Shari Redstone looks for new CBS directors in Viacom re-merger push</a></h4><ul>   <li>Viacom's jumping (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+1.9%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='green'>+2.7%</font>) and <a href='https://seekingalpha.com/symbol/CBS' title='CBS Corporation'>CBS</a> isn't (a quick downturn to <font color='red'>-2%</font>) as <i>The Wall Street Journal</i> notes Shari Redstone is <a href=\"https://www.wsj.com/articles/shari-redstone-wants-new-cbs-directors-renews-push-to-merge-cbs-and-viacom-1516217045\" target=\"_blank\">looking for new directors at CBS</a> as she pushes to re-merge the companies.</li>    <li>She may want to make the move this quarter, sources told the WSJ, and Redstone has reached out to (previously resistant) CBS chief Les Moonves to push the idea.</li><li>CBS is planning to propose replacing several names on the board when it meets in May, and Shari Redstone is gathering names of possible new candidates, according to the report.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322894-viacom-lower-rosenblatt-cuts-sell-amid-cbs-merger-chatter\" target=\"_blank\">Viacom lower as Rosenblatt cuts to Sell amid CBS merger chatter</a> (Jan. 16 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322709-viacom-cbs-jump-report-new-re-merger-pursuit\" target=\"_blank\">Viacom, CBS jump on report of new re-merger pursuit</a> (Jan. 12 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323343\" data-linked=\"WSJ: Shari Redstone looks for new CBS directors in Viacom re-merger push\" data-tweet=\"$VIA $VIA $VIAB - WSJ: Shari Redstone looks for new CBS directors in Viacom re-merger push https://seekingalpha.com/news/3323343-wsj-shari-redstone-looks-for-new-cbs-directors-in-viacom-re-merger-push?source=tweet\" data-url=\"https://seekingalpha.com/news/3323343-wsj-shari-redstone-looks-for-new-cbs-directors-in-viacom-re-merger-push\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323342\" data-ts=\"1516217672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLCA\" target=\"_blank\">SLCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323342-u-s-silica-started-buy-r-f-rafferty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Silica started with Buy at R.F. Rafferty</a></h4><ul>     <li>U.S. Silica (<a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='green'>+2%</font>) is higher after R.F. Lafferty initiates coverage with a <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11040514/r-f-lafferty-u-s-silica-offers-about-45-upside-potentia\" target=\"_blank\">Buy rating</a> and a $52 price target, saying SLCA is well positioned to benefit from higher demand for proppant from the oil and gas industry.</li>     <li>The oil and gas proppants segment accounted for 81% of SLCA's revenues during the first nine months of 2017, and the company's expected supply of up to 23.5M tons by mid-2018 would represent ~24% of the total market, the firm calculates.</li>     <li>Besides supplying frac sand to the market, SLCA also is capable of delivering product directly to the well site with its last-mile solutions through SandBox, Lafferty says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323342\" data-linked=\"U.S. Silica started with Buy at R.F. Rafferty\" data-tweet=\"$SLCA - U.S. Silica started with Buy at R.F. Rafferty https://seekingalpha.com/news/3323342-u-s-silica-started-buy-r-f-rafferty?source=tweet\" data-url=\"https://seekingalpha.com/news/3323342-u-s-silica-started-buy-r-f-rafferty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323335\" data-ts=\"1516216957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323335-ge-continues-lower-analysts-see-problems-potential-breakup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE continues lower as analysts see problems with potential breakup</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-4.4%</font>) sheds another 4%-plus following yesterday's 3% slide, wiping out its <a href=\"https://seekingalpha.com/news/3322457-ge-gains-10-percent-ytd-oppenheimer-analyst-remains-skeptical\" target=\"_blank\">heretofore strong start</a> to the new year, as analysts say the surprise charges announced yesterday (<a href=\"https://seekingalpha.com/news/3322817-general-electric-3-percent-insurance-charge\" target=\"_blank\">I</a>, <a href=\"https://seekingalpha.com/news/3322937-ge-breakup-announcement-come-soon-cnbc\" target=\"_blank\">II</a>, <a href=\"https://seekingalpha.com/news/3323110-ges-latest-bad-news-wall-street-worried-come\" target=\"_blank\">III</a>) <a href=\"https://www.reuters.com/article/us-ge-stocks/ges-2018-gains-wiped-out-as-worries-about-turnaround-plan-persist-idUSKBN1F62FV?il=0\" target=\"_blank\">further damage the company&rsquo;s credibility</a>.</li>     <li>J.P. Morgan says it is becomingly increasingly difficult to justify its $16 stock price target, as there may be \"<a href=\"https://www.cnbc.com/2018/01/17/ge-shares-crater-as-breakup-wont-be-a-magic-bullet-for-investors.html\" target=\"_blank\">many dis-synergies not incorporated</a>\" in its previous analysis of GE whose unknown risks may justify a further degraded value of $12-$16, closer to Cowen analyst Gautam Khanna's analysis of GE's sum-of-the-parts that suggests a breakup valuation of $11-$15/share.</li>     <li>Rather than break up into pieces, Jeffrey Sprague of Vertical Research Partners believes GE is more likely to sell its 62% stake in Baker Hughes (<a href='https://seekingalpha.com/symbol/BHGE' title='Baker Hughes, a GE company'>BHGE</a> <font color='green'>+0.4%</font>) and possibly spin off part of its aircraft leasing business.</li>     <li>&ldquo;Investors don&rsquo;t want conglomerates anymore and the other conglomerates are breaking up,&rdquo; says Melius Research's Scott Davis, who also thinks a breakup process would not be overly complicated as GE's liabilities could be assigned to the spinoffs and the bloated pension would get allocated according to the percentage of employees spun off, and debt also could be put into the units.</li>     <li>Davis believes the separate businesses would perform well, since GE typically is among the top three companies in any given sector where it has a presence.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323335\" data-linked=\"GE continues lower as analysts see problems with potential breakup\" data-tweet=\"$GE $GE $BKR - GE continues lower as analysts see problems with potential breakup https://seekingalpha.com/news/3323335-ge-continues-lower-analysts-see-problems-potential-breakup?source=tweet\" data-url=\"https://seekingalpha.com/news/3323335-ge-continues-lower-analysts-see-problems-potential-breakup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323333\" data-ts=\"1516216802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASML\" target=\"_blank\">ASML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323333-b-riley-raises-asml-price-target-recommends-amat-and-lam-research\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">B. Riley raises ASML price target, recommends AMAT and Lam Research</a></h4><ul><li>        B. Riley <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20180117131957ASML\" target=\"_blank\">raises</a> its ASML (<a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a> <font color='green'>+7.5%</font>) price target from $166 to $200 following the premarket earnings report.</li><li>               Firm says ASML exited CY17 with a strong Q4 beat and that while the Q1 outlook was lower, overall performance was better than expected.&nbsp;</li><li>               Earnings tailwinds were order and backlog strengths, which hint at strong CY18 Y/Y sales growth.&nbsp;</li><li>                  Firm thinks the target of CY20 EPS at &euro;9.00 is attainable. CY18 and CY19 EPS estimates increased to &euro;6.01 (was: &euro;5.22) and &euro;7.78 (was: &euro;7.04).    </li><li>               B. Riley does see better value in Buy-rated Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color='green'>+4.7%</font>) with a $71 price target and Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='green'>+6.5%</font>) with a $250 price target.&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323123-asml-holding-higher-5_7-percent-q4-profit-sales-beat\" target=\"_blank\">ASML Holding higher 5.7% after Q4 profit and sales beat</a> (Jan. 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323256-semiconductor-stocks-moving-asml-ichor-news\" target=\"_blank\">Semiconductor stocks moving after ASML, Ichor news</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323333\" data-linked=\"B. Riley raises ASML price target, recommends AMAT and Lam Research\" data-tweet=\"$ASML $ASML $AMAT - B. Riley raises ASML price target, recommends AMAT and Lam Research https://seekingalpha.com/news/3323333-b-riley-raises-asml-price-target-recommends-amat-and-lam-research?source=tweet\" data-url=\"https://seekingalpha.com/news/3323333-b-riley-raises-asml-price-target-recommends-amat-and-lam-research\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323329\" data-ts=\"1516215706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323329-energy-materials-top-gainers-losers-of-2-00-pm-1-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/17/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='green'>+7%</font>. SGY <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CRR' title='CARBO Ceramics Inc.'>CRR</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/ASIX' title='AdvanSix Inc.'>ASIX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ENSV' title='Enservco Corp.'>ENSV</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323329\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/17/2018)\" data-tweet=\"$USAU $DNR $TALO - Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/17/2018) https://seekingalpha.com/news/3323329-energy-materials-top-gainers-losers-of-2-00-pm-1-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323329-energy-materials-top-gainers-losers-of-2-00-pm-1-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323328\" data-ts=\"1516215260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/T\" target=\"_blank\">T</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323328-sprint-presses-free-year-promotion-in-new-shot-verizon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint presses free-year promotion in new shot at Verizon</a></h4><ul>   <li>With a couple of its <a href=\"https://seekingalpha.com/news/3321711-sprint-may-face-churn-longtime-key-promotions-end\" target=\"_blank\">best-known promotions wrapping up</a>, Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='red'>-1%</font>) is calling attention to a big one wrapping up this month: a free year of unlimited service for switchers who bring their device.</li>    <li>As FierceWireless' <a href=\"https://www.fiercewireless.com/wireless/targeting-verizon-users-sprint-revives-free-unlimited-for-a-year-promotion\" target=\"_blank\">Mike Dano points out</a>, while the promotion covers about three dozen phones, it targets one rival in particular: \"Stop feeling ripped off by Verizon.\" (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='red'>-0.2%</font>)</li>    <li>Verizon was also in Sprint's sights when it <a href=\"https://seekingalpha.com/news/3273220-sprint-promos-free-year-family-plan-shot-verizon\" target=\"_blank\">launched this promotion before</a>, what Craig Moffett called the \"most aggressive\" in U.S. wireless history, and it <a href=\"https://seekingalpha.com/news/3283820-sprint-plus-7_1-percent-posts-profit-first-time-three-years\" target=\"_blank\">juiced Sprint's quarter</a> then.</li>    <li>The deal runs through the end of the month. Sprint is expected to report quarterly results before the open on Tuesday, Jan. 30.</li>    <li>In other trading action among the Big Four: <a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a> <font color='green'>+0.3%</font>, <a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color='green'>+2.1%</font>.</li><li><strong>Updated:</strong> Sprint says that it's allowed switchers to take advantage of the promotion beyond last summer's expiration; it will end the offer Jan. 31.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323328\" data-linked=\"Sprint presses free-year promotion in new shot at Verizon\" data-tweet=\"$T $T $TMUS - Sprint presses free-year promotion in new shot at Verizon https://seekingalpha.com/news/3323328-sprint-presses-free-year-promotion-in-new-shot-verizon?source=tweet\" data-url=\"https://seekingalpha.com/news/3323328-sprint-presses-free-year-promotion-in-new-shot-verizon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323325\" data-ts=\"1516213628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTO\" target=\"_blank\">PRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323325-proteon-therapeutics-follows-through-on-recent-breakout-up-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteon Therapeutics follows through on recent breakout, up 19%</a></h4><ul><li>Thinly traded nano cap Proteon Therapeutics (<a href='https://seekingalpha.com/symbol/PRTO' title='Proteon Therapeutics'>PRTO</a> <font color='green'>+19.1%</font>) is up on a 4x surge in volume, albeit on turnover of only 205K shares, following through on last Thursday's breakout. Shares have rallied almost&nbsp;<font color='green'>50%</font>&nbsp;since then.</li><li>No particular news accounts for the action. On the data front, preliminary results from a second Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02414841?titles=patency-2&amp;spons=proteon&amp;phase=2&amp;rank=1\" target=\"_blank\">PATENCY-2</a>, assessing lead candidate vonapanitase's ability to extend the patency of radiocephalic fistulas (vascular access point for hemodialysis) in chronic kidney disease patients should be available later this year. The first Phase 3, PATENCY-1, failed to demonstrate a treatment effect over placebo.</li><li>On the financing front, the company raised $22M last June via the sale of convertible preferred stock which it says will be sufficient to fund operations into Q4 2019, more than enough time to report results from PATENCY-2. At the end of September 2017, its quick asset balance was $47.4M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3230179-proteons-lead-product-candidate-flunks-late-stage-study-chronic-kidney-disease-shares-plummet\" target=\"_blank\">Proteon's lead product candidate flunks late-stage study in chronic kidney disease; shares plummet 73% premarket</a> (Dec. 13, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323325\" data-linked=\"Proteon Therapeutics follows through on recent breakout, up 19%\" data-tweet=\"$PRTO - Proteon Therapeutics follows through on recent breakout, up 19% https://seekingalpha.com/news/3323325-proteon-therapeutics-follows-through-on-recent-breakout-up-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3323325-proteon-therapeutics-follows-through-on-recent-breakout-up-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323323\" data-ts=\"1516212774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323323-broadcom-goes-red-on-word-of-ftc-competition-investigation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcom goes red on word of FTC competition investigation</a></h4><ul>   <li>Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>) has tumbled into negative ground on the day, quickly <font color='red'>down 1%</font>, on word from <i>The Wall Street Journal</i> that the <a href=\"https://www.wsj.com/articles/ftc-investigates-broadcom-over-negotiations-with-customers-1516212396?mod=breakingnews\" target=\"_blank\">Federal Trade Commission is investigating</a> whether it engaged in anticompetitive tactics in customer negotiations.</li>    <li>The company has changed some contracts so they call for customers to buy a percentage of output of a certain item, rather than an absolute number, sources told WSJ.</li>    <li>The probe has been ongoing for months, according to the report.</li><li>The limited scope of the probe reportedly does not cover Broadcom's wireless segment.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323323\" data-linked=\"Broadcom goes red on word of FTC competition investigation\" data-tweet=\"$AVGO - Broadcom goes red on word of FTC competition investigation https://seekingalpha.com/news/3323323-broadcom-goes-red-on-word-of-ftc-competition-investigation?source=tweet\" data-url=\"https://seekingalpha.com/news/3323323-broadcom-goes-red-on-word-of-ftc-competition-investigation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323321\" data-ts=\"1516212090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323321-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='green'>+9%</font>.<a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties'>IIPR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/QTS' title='QTS Realty Trust, Inc.'>QTS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323321\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$WHLR $SIEB $YRD - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3323321-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3323321-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323317\" data-ts=\"1516211386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323317-midday-gainers-losers-1-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (1/17/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/PRTO' title='Proteon Therapeutics'>PRTO</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ZAGG' title='ZAGG Inc'>ZAGG</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HIVE' title='Aerohive Networks, Inc.'>HIVE</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/NEWA' title='Newater Technology, Inc.'>NEWA</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ATEN' title='A10 Networks, Inc.'>ATEN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/FTD' title='FTD Companies, Inc.'>FTD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323317\" data-linked=\"Midday Gainers / Losers (1/17/2018)\" data-tweet=\"$JUNO $ENLV $NURO - Midday Gainers / Losers (1/17/2018) https://seekingalpha.com/news/3323317-midday-gainers-losers-1-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323317-midday-gainers-losers-1-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323316\" data-ts=\"1516211311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLR\" target=\"_blank\">DLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323316-digital-realty-dips-credit-suisse-starts-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Realty dips as Credit Suisse starts at Neutral</a></h4><ul>   <li>Digital Realty (NYSE:<a href='https://seekingalpha.com/symbol/DLR' title='Digital Realty Trust, Inc.'>DLR</a>) is <font color='red'>2.1% lower</font> today after an initiation at Neutral by Credit Suisse, which sees a company still in progress on a pivot away from its pure-play roots in wholesale data centers.</li>    <li>The company is making headway on keeping up with peers by offering various lease sizes and deployment types, the firm says.</li>    <li>It's lagging peers on capital deployment intensity relative to revenue growth, though. (h/t Bloomberg)</li>    <li>Analyst Sami Badri has a $95 price target, a street low, implying 10% downside from current pricing.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323316\" data-linked=\"Digital Realty dips as Credit Suisse starts at Neutral\" data-tweet=\"$DLR - Digital Realty dips as Credit Suisse starts at Neutral https://seekingalpha.com/news/3323316-digital-realty-dips-credit-suisse-starts-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3323316-digital-realty-dips-credit-suisse-starts-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323314\" data-ts=\"1516210766\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323314-investors-unmoved-exelixis-late-stage-liver-cancer-data-on-cabozantinib-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors unmoved by Exelixis&#39; late-stage liver cancer data on cabozantinib; shares down 9%</a></h4><ul><li>Exelixis (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='red'>-9%</font>) is down on a 67% spike in volume on the heels of its <a href=\"https://seekingalpha.com/pr/17048308-exelixis-ipsen-announce-phase-3-trial-results-cabozantinib-demonstrating-significant-overall\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial assessing lead drug cabozantinib in previously treated hepatocellular carcinoma &#40;HCC&#41;.</li><li>The study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01908426?titles=celestial&amp;spons=exelixis&amp;phase=2&amp;rank=1\" target=\"_blank\">CELESTIAL</a>, demonstrated the superiority of cabozantinib over placebo in median overall survival &#40;OS&#41; (10.2 months vs. 8.0 months; p=0.0049), median progression-free survival &#40;PFS&#41; (5.2 months vs. 1.9 months; p&lt;0.0001) and objective response rate &#40;ORR&#41; (4% vs. 0.4%; p=0.0086). The disease control rate (responders + those with stable disease) was 64% in the treatment group compared to 33% for placebo.</li><li>In a subgroup of HCC patients previously with Bayer's NEXAVAR (sorafenib) only, median OS was 11.3 months (7.2 months for placebo) and median PFS was 5.5 months (placebo: 1.9 months).</li><li>Investors appear disappointed that there was not more separation from Bayer's (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a>) <a href=\"https://www.hcp.stivarga-us.com/Hepatocellular-Carcinoma/efficacy-in-RESORCE/\" target=\"_blank\">STIVARGA </a>(regorafenib), approved in the U.S. for second-line HCC last April. <a href=\"http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf\" target=\"_blank\">Data </a>from the Phase 3 RESORCE study showed median OS of 10.6 months, median PFS of 3.4 months and an ORR of 7%.</li><li><a href=\"http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf\" target=\"_blank\">Late-stage data</a> for NEXAVAR in a first-line setting in HCC showed median OS of 10.7 months and median PFS of 5.5 months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323314\" data-linked=\"Investors unmoved by Exelixis&#39; late-stage liver cancer data on cabozantinib; shares down 9%\" data-tweet=\"$EXEL $EXEL $BAYRY - Investors unmoved by Exelixis&#39; late-stage liver cancer data on cabozantinib; shares down 9% https://seekingalpha.com/news/3323314-investors-unmoved-exelixis-late-stage-liver-cancer-data-on-cabozantinib-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3323314-investors-unmoved-exelixis-late-stage-liver-cancer-data-on-cabozantinib-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323312\" data-ts=\"1516210663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADNT\" target=\"_blank\">ADNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323312-adientminus-7-q1-results-expected-to-be-hurt-ss-and-m-headwinds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adient -7% as Q1 results expected to be hurt by SS&amp;M headwinds</a></h4><ul>     <li>Adient (<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a> <font color='red'>-7.3%</font>) is sharply lower after a <a href=\"https://www.sec.gov/Archives/edgar/data/1670541/000119312518011214/d455863dex991.htm\" target=\"_blank\">slide presentation</a> says Q1 results will be \"significantly\" impacted by headwinds affecting its Seat Structures &amp; Mechanisms business including commodity prices and availability as well as launch inefficiencies, which have intensified since the company's Q4 earnings call.</li>     <li>Despite growth from China operations and management's efforts to mitigate the near-term challenges, ADNT says overall margins likely will take a \"modest step backwards\" in 2018.</li>     <li>Shares are lower despite <a href=\"https://seekingalpha.com/news/3323091-boeing-adient-launch-jv-design-build-airplane-seats\" target=\"_blank\">yesterday's news</a> that ADNT entered a joint venture with Boeing to develop, manufacture and sell airplane seats to airlines and aircraft leasing companies.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323312\" data-linked=\"Adient -7% as Q1 results expected to be hurt by SS&amp;M headwinds\" data-tweet=\"$ADNT - Adient -7% as Q1 results expected to be hurt by SS&amp;M headwinds https://seekingalpha.com/news/3323312-adientminus-7-q1-results-expected-to-be-hurt-ss-and-m-headwinds?source=tweet\" data-url=\"https://seekingalpha.com/news/3323312-adientminus-7-q1-results-expected-to-be-hurt-ss-and-m-headwinds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323300\" data-ts=\"1516208502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323300-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ETH' title='Ethan Allen Interiors Inc.'>ETH</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323300\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$FFHL $SGOC $DFBG-OLD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3323300-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3323300-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323296\" data-ts=\"1516207593\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOS\" target=\"_blank\">MOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323296-mosaic-cf-industries-continue-to-slide-on-fertilizer-market-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mosaic, CF Industries continue to slide on fertilizer market concerns</a></h4><ul>     <li>Mosaic (<a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='red'>-1.4%</font>) and CF Industries (<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='red'>-2%</font>) extend yesterday's sharp losses for combined two-day declines of 7% and 8%, respectively, a day after Credit Suisse analyst reiterated a cautious view of the fertilizer sector, seeing little to no evidence of improvement in key global demand drivers.</li>     <li>Credit Suisse sees a significant degree of new supply previously planned to hit in 2017 which will now arrive this year, and that fertilizer  markets will remain supply driven in 2018, driving volatile pricing and keeping profitability \"lower for longer.\"</li>     <li>The firm thinks MOS will face a challenging 2018, reiterating an Underperform rating as phosphate prices and margins likely will disappoint, while its top pick in the sector is FMC Corp. (<a href='https://seekingalpha.com/symbol/FMC' title='FMC Corporation'>FMC</a> <font color='red'>-0.7%</font>), citing greater opportunity for revenue  synergies in the ag business, especially in India, as well as  recent strength in lithium pricing.</li>     <li>Credit Suisse believes CF's cost-advantaged position should see the fertilizer business generate solid cash margins despite pricing volatility, but Hedgeye reportedly says it sees 50%-plus downside risk in CF shares, as lower nitrogen imports are not a sign of an improving market.</li>     <li>The firm rates Nutrien &lt;NTR&gt; as Neutral, seeing potash headwinds mounting in H2 2018.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323296\" data-linked=\"Mosaic, CF Industries continue to slide on fertilizer market concerns\" data-tweet=\"$MOS $MOS $CF - Mosaic, CF Industries continue to slide on fertilizer market concerns https://seekingalpha.com/news/3323296-mosaic-cf-industries-continue-to-slide-on-fertilizer-market-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3323296-mosaic-cf-industries-continue-to-slide-on-fertilizer-market-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323295\" data-ts=\"1516207325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323295-canaccord-raises-qualcomm-price-target-to-26-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canaccord raises Qualcomm price target to 26% upside</a></h4><ul><li>        Canaccord Genuity <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20180117105604QCOM\" target=\"_blank\">raises</a> its Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) price target by $3 to $86 after the company&rsquo;s shareholder letter. The price target is 26% higher than yesterday&rsquo;s closing price.</li><li>           &rdquo;Qualcomm&rsquo;s acquisition of NXP remains on track and will create a company with significant earnings power and cash flow, developing into a clear industry leader in the mobile, IoT, and automotive semiconductor markets backed by the extremely strong combined IP portfolio of Qualcomm, NXP, and Freescale,&rdquo; writes analyst T. Michael Walkley. </li><li>           The firm also believes Apple and Qualcomm will ultimately settle their legal battles. &nbsp; </li><li>        Qualcomm shares are<font color='green'> up 0.4%</font>&nbsp;to $68.53.&nbsp; <br /> </li><li>Previously: <a href=\"https://seekingalpha.com/news/3323236-macquarie-raises-qualcomm-price-target-broadcom-price-cuts\" target=\"_blank\">Macquarie raises Qualcomm price target on Broadcom, price cuts</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323295\" data-linked=\"Canaccord raises Qualcomm price target to 26% upside\" data-tweet=\"$QCOM - Canaccord raises Qualcomm price target to 26% upside https://seekingalpha.com/news/3323295-canaccord-raises-qualcomm-price-target-to-26-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3323295-canaccord-raises-qualcomm-price-target-to-26-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323294\" data-ts=\"1516206909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RLMD\" target=\"_blank\">RLMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323294-relmada-nabs-expanded-rights-to-cns-candidate-dextromethadone-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Relmada nabs expanded rights to CNS candidate dextromethadone; shares ahead 8%</a></h4><ul><li>Relmada Therapeutics (<a href='https://seekingalpha.com/symbol/RLMD' title='Relmada Therapeutics, Inc.'>OTCQB:RLMD</a> <font color='green'>+8.3%</font>) has <a href=\"https://seekingalpha.com/pr/17048690-relmada-therapeutics-acquires-global-rights-develop-market-dextromethadone-treatment\" target=\"_blank\">acquired </a>global rights to develop and commercialize lead candidate dextromethadone (REL-1017) for the treatment of neurological conditions, including certain rare diseases, that affect the central nervous system &#40;CNS&#41;. It previously owned the rights to the drug for psychological and psychiatric disorders, including depression, anxiety, fatigue and mood instability. Financial terms are not disclosed.</li><li>A Phase 2a study assessing dextromethadone for the adjunctive treatment of major depressive disorder, a Fast Track designation in the U.S., should launch no later than Q2.</li><li><a href=\"http://www.relmada.com/product-candidates/rel-1017-d-methadone\" target=\"_blank\">Dextromethadone</a>,&nbsp;an N-methyl-D-aspartate &#40;NMDA&#41; receptor antagonist, is a single isomer of methadone but has no opioid- or ketamine-like toxicities. It is being developed to treat neuropathic pain in addition to depression.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257040-relmadas-lead-product-candidate-relminus-1017-fast-trackd-mdd-shares-ahead-20-percent\" target=\"_blank\">Relmada's lead product candidate REL-1017 Fast Track'd for MDD; shares ahead 20% premarket</a> (April 13, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323294\" data-linked=\"Relmada nabs expanded rights to CNS candidate dextromethadone; shares ahead 8%\" data-tweet=\"$RLMD - Relmada nabs expanded rights to CNS candidate dextromethadone; shares ahead 8% https://seekingalpha.com/news/3323294-relmada-nabs-expanded-rights-to-cns-candidate-dextromethadone-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3323294-relmada-nabs-expanded-rights-to-cns-candidate-dextromethadone-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323293\" data-ts=\"1516206615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323293-workdayplus-1_3-on-duo-security-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday +1.3% on Duo Security partnership</a></h4><ul><li>        Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>) <a href=\"https://seekingalpha.com/pr/17048855-workday-expands-security-toolset-duo-partnership\" target=\"_blank\">announces</a> a partnership with Duo Security, which specializes in trusted access and multi-factor authentication technologies.</li><li>               Workday will integrate Duo&rsquo;s MFA functionality within the Workday user interface to offer customers further safeguards to mitigate phishing incidents.&nbsp;</li><li>                  Workday plans to make the Duo solutions available in 1H18. &nbsp;   </li><li>               Workday shares are&nbsp;<font color='green'>up 1.3%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322996-workday-acquires-enterprise-ai-company\" target=\"_blank\">Workday acquires enterprise AI company</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323293\" data-linked=\"Workday +1.3% on Duo Security partnership\" data-tweet=\"$WDAY - Workday +1.3% on Duo Security partnership https://seekingalpha.com/news/3323293-workdayplus-1_3-on-duo-security-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3323293-workdayplus-1_3-on-duo-security-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323292\" data-ts=\"1516206569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSO\" target=\"_blank\">PSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323292-pearsonminus-3_9-after-warning-of-drag-in-north-american-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pearson -3.9% after warning of drag in North American sales</a></h4><ul>   <li>Pearson (NYSE:<a href='https://seekingalpha.com/symbol/PSO' title='Pearson plc'>PSO</a>) is <font color='red'>down 3.9%</font> in NYSE trading after warning that 2018 earnings will be <a href=\"https://finance.yahoo.com/news/pearson-sees-2018-growth-fx-073501307.html\" target=\"_blank\">pressured by North American results</a>.</li>    <li>Sales of U.S. higher education course materials are expected to fall 3% on an underlying basis, it said, at the low end of its guidance.</li>    <li>Higher ed courseware is about a quarter of Pearson and the rest is doing well, says CEO John Fallon: \"We have said we are running Pearson on the basis that higher ed courseware is going to decline in underlying terms by about 5 or 6 percent per year through to the end of 2019 at which point we expect it to stabilize and start to grow again.\"</li>    <li>It forecast 2018 operating profit of &pound;520M-&pound;560M, which would represent underlying growth after accounting for asset sales and forex.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323292\" data-linked=\"Pearson -3.9% after warning of drag in North American sales\" data-tweet=\"$PSO - Pearson -3.9% after warning of drag in North American sales https://seekingalpha.com/news/3323292-pearsonminus-3_9-after-warning-of-drag-in-north-american-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3323292-pearsonminus-3_9-after-warning-of-drag-in-north-american-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323289\" data-ts=\"1516206206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323289-bofaml-raises-apples-price-target-to-1_1t-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML raises Apple&#39;s price target to $1.1T valuation</a></h4><ul><li>Bank of America Merrill Lynch <a href=\"https://www.cnbc.com/2018/01/17/apple-gets-its-most-bullish-call-yet-220-from-bofa-merrill-lynch.html\" target=\"_blank\">raises</a> its Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) price target from $180 to $220 while reiterating a Buy rating. The price target is 25% above yesterday&rsquo;s closing price and would represent a $1.1T market valuation.</li><li>&rdquo;We remain bullish on potential for cash repatriation, lower tax rates, and the potential for positive estimate revisions heading into 2019. A smoother iPhone cycle (no boom-bust) should drive increased stability in earnings, commanding a higher multiple,&rdquo; writes analyst Wamsi Mohan.</li><li>Mohan expects Apple to repatriate $236B of its $253B in overseas cash under the 15.5% tax rate in the tax reform bill and notes that cash could go towards buybacks, dividends, or M&amp;A.</li><li>Apple shares are&nbsp;<font color='red'>down 0.2%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323180-longbow-downgrades-apple-lower-iphone-forecast\" target=\"_blank\">Longbow downgrades Apple on lower iPhone forecast</a> (Jan. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323289\" data-linked=\"BofAML raises Apple&#39;s price target to $1.1T valuation\" data-tweet=\"$AAPL - BofAML raises Apple&#39;s price target to $1.1T valuation https://seekingalpha.com/news/3323289-bofaml-raises-apples-price-target-to-1_1t-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3323289-bofaml-raises-apples-price-target-to-1_1t-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>78&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323287\" data-ts=\"1516205708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GT\" target=\"_blank\">GT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323287-goodyear-tire-jumps-execs-present-in-detroit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goodyear Tire jumps as execs present in Detroit</a></h4><ul>     <li>Goodyear Tire &amp; Rubber (<a href='https://seekingalpha.com/symbol/GT' title='Goodyear Tire & Rubber Co.'>GT</a> <font color='green'>+3.6%</font>) is tracking higher as management presents at the Deutsch Bank 2018 Global Auto Industry Conference in conjunction with the Detroit Auto Show.</li>     <li>Bloomberg reports that the company disclosed tire volume for Q4 ahead of expectations.</li>     <li><a href=\"https://cc.talkpoint.com/deut001/011618a_as/?entity=20_6W5YWCM\" target=\"_blank\">Goodyear presentation webcast </a></li><li><a href=\"https://seekingalpha.com/news/search?query=%23DetroitAutoShow18\" target=\"_blank\">#DetroitAutoShow18</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3323287\" data-linked=\"Goodyear Tire jumps as execs present in Detroit\" data-tweet=\"$GT - Goodyear Tire jumps as execs present in Detroit https://seekingalpha.com/news/3323287-goodyear-tire-jumps-execs-present-in-detroit?source=tweet\" data-url=\"https://seekingalpha.com/news/3323287-goodyear-tire-jumps-execs-present-in-detroit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323286\" data-ts=\"1516205579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONTX\" target=\"_blank\">ONTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323286-onconova-stays-course-late-stage-study-of-rigosertib-in-mds-shares-up-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Onconova stays the course with late-stage study of rigosertib in MDS; shares up 13%</a></h4><ul><li>Thinly traded nano cap Onconova Therapeutics (<a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+12.6%</font>) is up on a healthy 36x surge in volume (although down almost 30% from the intraday high of $2.66) on the heels of its <a href=\"https://seekingalpha.com/pr/17048632-onconova-moving-forward-phase-3-inspire-pivotal-trial-increased-sample-size-following\" target=\"_blank\">announcement </a>that it will advance the Phase 3 INSPIRE study assessing lead candidate rigosertib in patients with treatment-resistant myelodysplastic syndromes &#40;MDS&#41; and will expand enrollment.</li><li>The company made its decision following an interim analysis by the independent Data Monitoring Committee. It remains blinded to the preliminary data.</li><li>Rigosertib is a small molecule that inhibits cellular signaling by acting as a&nbsp;<a href=\"https://en.wikipedia.org/wiki/Ras_subfamily\" target=\"_blank\">Ras protein</a>&nbsp;mimetic. Ras is a family of proteins that are involved in transmitting signals within cells. When switched \"on\", it activates other proteins that ultimately turn on genes involved in cell growth, differentiation and survival.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299972-onconova-18-percent-positive-phase-3-outlook-lead-candidate-rigosertib\" target=\"_blank\">Onconova up 18% on positive Phase 3 outlook on lead candidate rigosertib</a> (Oct. 9, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323286\" data-linked=\"Onconova stays the course with late-stage study of rigosertib in MDS; shares up 13%\" data-tweet=\"$ONTX - Onconova stays the course with late-stage study of rigosertib in MDS; shares up 13% https://seekingalpha.com/news/3323286-onconova-stays-course-late-stage-study-of-rigosertib-in-mds-shares-up-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3323286-onconova-stays-course-late-stage-study-of-rigosertib-in-mds-shares-up-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323284\" data-ts=\"1516205393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323284-banks-lower-after-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks lower after Q4 results</a></h4><ul><li>Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-2.3%</font>), Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-3.2%</font>), and U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-2.8%</font>) are all nicely lower after topping earnings estimates for Q4. In BofA's case, one might expect the bulls to take a breather after the stock's major run higher, but Goldman and U.S. Bancorp have been laggards over the past year.</li><li>KBW's Brian Kleinhanzi takes note of sluggish loan growth at Bank of America, not to mention disappointing mortgage banking fees.</li><li>The continuing plunge in trading revenue story for Goldman may be getting a bit long in the tooth, but a 50% drop in FICC business in Q4 was still a shock. While the bank's adjusted bottom line beat headline estimates, Nomura's Steven Chubak says Goldman benefitted from a lower tax rate. Adjusting again, he figures, core EPS at $4.97 vs. estimates of $5.01.</li><li>On U.S. Bancorp, Evercore's John Pancari says the expense outlook was higher than hoped and loan growth headwinds look to continue in the near-term.</li><li>Source: Bloomberg's Felice Maranz</li><li>The major averages are in the green, but some bank-related ETFs: (<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> <font color='red'>-0.2%</font>), (<a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> <font color='red'>-0.3%</font>), (<a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> <font color='red'>-0.4%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323284\" data-linked=\"Banks lower after Q4 results\" data-tweet=\"$BAC $BAC $GS - Banks lower after Q4 results https://seekingalpha.com/news/3323284-banks-lower-after-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3323284-banks-lower-after-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323251\" data-ts=\"1516204858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323251-healthcare-top-5-gainers-losers-of-11-00-1-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/17/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+63%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/PRTO' title='Proteon Therapeutics'>PRTO</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323251\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/17/2018)\" data-tweet=\"$ENLV $JUNO $NURO - Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/17/2018) https://seekingalpha.com/news/3323251-healthcare-top-5-gainers-losers-of-11-00-1-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323251-healthcare-top-5-gainers-losers-of-11-00-1-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323280\" data-ts=\"1516204622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORPN\" target=\"_blank\">ORPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323280-bioblast-up-big-news-scarceplus-69\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioblast up big but news scarce, +69%</a></h4><ul><li>Thinly traded nano cap Bioblast Pharma (<a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+69.2%</font>) is up a whopping 56x surge in volume. No particular news accounts for the action but the stock has shown similar behavior in the past followed by a roundtrip. Shares were up&nbsp;<font color='green'>128%&nbsp;</font>intraday before retracing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319437-bioblast-pharma-32-percent-triggers-volatility-halt\" target=\"_blank\">Bioblast Pharma up 32%, triggers volatility halt</a> (Dec. 20, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323280\" data-linked=\"Bioblast up big but news scarce, +69%\" data-tweet=\"$ORPN $ENLV - Bioblast up big but news scarce, +69% https://seekingalpha.com/news/3323280-bioblast-up-big-news-scarceplus-69?source=tweet\" data-url=\"https://seekingalpha.com/news/3323280-bioblast-up-big-news-scarceplus-69\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323276\" data-ts=\"1516204003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACLS\" target=\"_blank\">ACLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323276-acelis-under-pressure-after-lowering-target-margins-shares-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acelis under pressure after lowering target margins; shares down 8%</a></h4><ul><li>Axcelis Technologies (<a href='https://seekingalpha.com/symbol/ACLS' title='Axcelis Technologies, Inc.'>ACLS</a> <font color='red'>-8.3%</font>) is down in early trading on the heels of its presentation at the Needham Growth Conference during which it presented softer guidance on margins due to product mix and pricing pressure.</li><li>Based on target revenue of $450M for the year, the company expects ~39% gross margin (down from 40 - 42%) and operating margin of ~14% (vs. 14 - 17%).</li><li>Analysts say increased pricing pressure, most likely from Applied Materials, should intensify as ACLS gains market share.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3323276\" data-linked=\"Acelis under pressure after lowering target margins; shares down 8%\" data-tweet=\"$ACLS - Acelis under pressure after lowering target margins; shares down 8% https://seekingalpha.com/news/3323276-acelis-under-pressure-after-lowering-target-margins-shares-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3323276-acelis-under-pressure-after-lowering-target-margins-shares-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323271\" data-ts=\"1516203182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXAS\" target=\"_blank\">EXAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323271-exact-sciences-under-pressure-on-potential-crc-blood-screening-test-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exact Sciences under pressure on potential CRC blood screening test; shares down 9%</a></h4><ul><li>Exact Sciences (<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='red'>-8.6%</font>) is down in early trading on light volume on the heels of an ASCO <a href=\"https://www.asco.org/about-asco/press-center/news-releases/liquid-biopsy-test-shows-promise-detecting-early-stage\" target=\"_blank\">announcement </a>of a new study assessing a liquid biopsy test for colorectal cancer &#40;CRC&#41; that showed up to 88% accuracy. The results of the Taiwan-based study will be presented at the ASCO-GI Symposium in San Francisco later this week.</li><li>Researchers collected blood samples from 620 adult patients who underwent routine colonoscopies or had confirmed CRC. Based on the results from colonoscopy and biopsy, 438 (70.6%) had either pre-cancerous growths or early-to-late-stage CRC.</li><li>The sensitivity (correctly identifying true positives) of the blood test, an assay that captures rare circulating tumor cells, was 77% in the pre-cancerous lesion group and 87% in the confirmed CRC group.</li><li>The specificity (correctly identifying true negatives) was 97%.</li><li>The overall accuracy (sensitivity and specificity) was 84 - 88% between pre-cancerous and cancerous samples.</li><li>Co-author Ashish Nimgaonkar, M.D., says over 80% of patients reluctant to undergo a colonoscopy would be prefer a blood test over a stool-based test. He adds that the blood test can potentially be offered for less than $100.</li><li>Exact Sciences' Cologuard is <a href=\"https://www.cologuardtest.com/hcp/about-cologuard/performance-effectiveness\" target=\"_blank\">92% sensitive</a> and 87% specific in confirmed CRC, but its performance goes down significantly in pre-cancerous lesions with a sensitivity of only 42% (<a href=\"https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130017c.pdf\" target=\"_blank\">Cologuard Physician Brochure</a>, page 8).</li></ul><div class=\"tiny-share-widget\" data-id=\"3323271\" data-linked=\"Exact Sciences under pressure on potential CRC blood screening test; shares down 9%\" data-tweet=\"$EXAS - Exact Sciences under pressure on potential CRC blood screening test; shares down 9% https://seekingalpha.com/news/3323271-exact-sciences-under-pressure-on-potential-crc-blood-screening-test-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3323271-exact-sciences-under-pressure-on-potential-crc-blood-screening-test-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>182&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323269\" data-ts=\"1516202962\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQNS\" target=\"_blank\">SQNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323269-sequansminus-14_9-after-pricing-ads-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sequans -14.9% after pricing ADS public offering</a></h4><ul><li>        Sequans Communications (NYSE:<a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a>) <a href=\"https://seekingalpha.com/pr/17048825-sequans-communications-s-announces-pricing-underwritten-public-offering-american-depositary\" target=\"_blank\">announces</a> pricing of public offering of American Depositary Shares representing 12.5M ordinary shares at a price of $1.60 per ADS.</li><li>               Underwriters have a 30-day option to acquire an additional 1,875,000 ADSs to cover overallotments.&nbsp;</li><li>               Sequans expects to receive $18.2M in net proceeds that will go towards general corporate purposes.&nbsp;</li><li>               Offering expected to close January 19.&nbsp;</li><li>               Sequans shares are&nbsp;<font color='red'>down 14.9%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3323269\" data-linked=\"Sequans -14.9% after pricing ADS public offering\" data-tweet=\"$SQNS - Sequans -14.9% after pricing ADS public offering https://seekingalpha.com/news/3323269-sequansminus-14_9-after-pricing-ads-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3323269-sequansminus-14_9-after-pricing-ads-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323268\" data-ts=\"1516202789\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323268-roku-offers-new-tools-for-ott-marketing-measurement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku offers new tools for OTT marketing measurement</a></h4><ul>   <li>Roku (<a href=\"http://seekingalpha.com/symbol/ROKU\" target=\"_blank\">ROKU</a> <font color='green'>+5.9%</font>) is rolling out a <a href=\"https://seekingalpha.com/pr/17048954-roku-introduces-new-ad-insights-suite-enable-marketers-better-quantify-ott-advertising\" target=\"_blank\">new Ad Insights suite</a> to help marketers measure results in over-the-top services.</li>    <li>Customers will be able to measure campaign reach and effectiveness across both linear TV and OTT service, balancing views as customers migrate toward streaming viewing.</li>    <li>The new product includes Reach Insights, Tune-In Insights (to measure effectiveness of promotions), Cord-Cutter Insights (for those without traditional pay TV) and Survey Insights.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323268\" data-linked=\"Roku offers new tools for OTT marketing measurement\" data-tweet=\"$ROKU - Roku offers new tools for OTT marketing measurement https://seekingalpha.com/news/3323268-roku-offers-new-tools-for-ott-marketing-measurement?source=tweet\" data-url=\"https://seekingalpha.com/news/3323268-roku-offers-new-tools-for-ott-marketing-measurement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323263\" data-ts=\"1516202420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CA\" target=\"_blank\">CA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323263-ca-joins-collaborative-robotics-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CA joins collaborative robotics program</a></h4><ul><li>        CA Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/CA' title='CA Inc.'>CA</a>) <a href=\"http://investor.ca.com/releasedetail.cfm?ReleaseID=1054525\" target=\"_blank\">will partner</a> with the collaborative robotics project Cobotics that works alongside Finland&rsquo;s Tampere University of Technology and IT software company Tieto. &nbsp;</li><li>        The Cobotics collab will explore building safe, secure, and effective human-to-robot workflows with proper control and execution.</li><li>               Funding for the project comes from Tekes, the Finnish Funding Agency for Innovation, Tampere University, Tieto, and CA.&nbsp;</li><li>               The first phase of the project is expected to conclude in December 2018.&nbsp;</li><li>               CA shares are&nbsp;<font color='green'>up 0.7%</font>.&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3323263\" data-linked=\"CA joins collaborative robotics program\" data-tweet=\"$CA - CA joins collaborative robotics program https://seekingalpha.com/news/3323263-ca-joins-collaborative-robotics-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3323263-ca-joins-collaborative-robotics-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323259\" data-ts=\"1516202020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323259-erosplus-2_9-after-renewing-deal-reliance-jio\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros +2.9% after renewing deal with Reliance Jio</a></h4><ul>   <li>Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) is <font color='green'>up 2.9%</font> in early going after announcing a <a href=\"https://seekingalpha.com/pr/17048889-eros-now-announces-renewal-platform-integration-deal-reliance-jio\" target=\"_blank\">renewal deal</a> for its platform integration partnership with mobile service provider Reliance Jio.</li>    <li>The Eros Now direct-to-consumer service will be available to Jio subscribers under the deal.</li>    <li>\"With over 160M 4G mobile subscribers of Jio, the partnership will allow Eros to target to this large subscriber base,\" says Eros Digital CEO Rishika Lulla Singh.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323259\" data-linked=\"Eros +2.9% after renewing deal with Reliance Jio\" data-tweet=\"$EROS - Eros +2.9% after renewing deal with Reliance Jio https://seekingalpha.com/news/3323259-erosplus-2_9-after-renewing-deal-reliance-jio?source=tweet\" data-url=\"https://seekingalpha.com/news/3323259-erosplus-2_9-after-renewing-deal-reliance-jio\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323258\" data-ts=\"1516201922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323258-bank-of-canada-hikes-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of Canada hikes again</a></h4><ul><li>As expected, the<a href=\"http://www.bankofcanada.ca/2018/01/fad-press-release-2018-01-17/\" target=\"_blank\"> Bank of Canada lifts</a> its benchmark overnight rate by 25 basis points to 1.25%.</li><li>The statement offers a balance of hawkish and dovish, noting strong recent data, inflation close to target, an economy operating nearly at capacity, but concern over Nafta as clouding the outlook.</li><li>The loonie (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXC' title='CurrencyShares Canadian Dollar Trust ETF'>FXC</a>) all over the place, but currently&nbsp;<font color='red'>down 0.4%</font>&nbsp;vs. the greenback at $0.8009.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWC' title='iShares MSCI Canada ETF'>EWC</a>, <a href='https://seekingalpha.com/symbol/CNDA' title='IQ Canada Small Cap ETF'>CNDA</a>, <a href='https://seekingalpha.com/symbol/EWCS' title='iShares MSCI Canada Small Cap Index ETF'>EWCS</a>, <a href='https://seekingalpha.com/symbol/QCAN' title='SPDR MSCI Canada Quality Mix ETF'>QCAN</a>, <a href='https://seekingalpha.com/symbol/FCAN' title='First Trust Canada AlphaDex ETF'>FCAN</a>, <a href='https://seekingalpha.com/symbol/HEWC' title='iShares Currency Hedged MSCI Canada ETF'>HEWC</a>, <a href='https://seekingalpha.com/symbol/FLCA' title='Franklin FTSE Canada ETF'>FLCA</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3323258\" data-linked=\"Bank of Canada hikes again\" data-tweet=\"$FXC $EWC $CNDA - Bank of Canada hikes again https://seekingalpha.com/news/3323258-bank-of-canada-hikes-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3323258-bank-of-canada-hikes-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323257\" data-ts=\"1516201838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323257-boot-barn-bid-down-after-secondary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boot Barn bid down after secondary</a></h4><ul>     <li>Boot Barn (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color='red'>-6.2%</font>) trades lower despite posting preliminary FQ3 same-store sales growth of 5.2% and total sales of $225M vs. $221M consensus.</li>     <li>Investors appear to be reacting to the company's secondary offering of 5.5M shares on behalf of selling shareholders.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3323151-boot-barn-announces-secondary-offering\" target=\"_blank\">Boot Barn announces secondary offering</a> (Jan. 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323257\" data-linked=\"Boot Barn bid down after secondary\" data-tweet=\"$BOOT - Boot Barn bid down after secondary https://seekingalpha.com/news/3323257-boot-barn-bid-down-after-secondary?source=tweet\" data-url=\"https://seekingalpha.com/news/3323257-boot-barn-bid-down-after-secondary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323256\" data-ts=\"1516201524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASML\" target=\"_blank\">ASML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323256-semiconductor-stocks-moving-after-asml-ichor-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semiconductor stocks moving after ASML, Ichor news</a></h4><ul><li>Semiconductor equipment stocks are on the move following ASML&rsquo;s (<a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a> <font color='green'>+6%</font>) premarket earnings report and Ichor&rsquo;s (<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='green'>+8.1%</font>) upside prelim results and guidance.</li><li>Movers: Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color='green'>+2.3%</font>), Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='green'>+3.8%</font>), and KLA-Tencor (<a href='https://seekingalpha.com/symbol/KLAC' title='KLA-Tencor Corporation'>KLAC</a> <font color='green'>+2.3%</font>).</li><li>The Philadelphia Semiconductor Index is&nbsp;<font color='green'>up 1%.</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3323123-asml-holding-higher-5_7-percent-q4-profit-sales-beat\" target=\"_blank\">ASML Holding higher 5.7% after Q4 profit and sales beat</a> (Jan. 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323250-ichor-plus-8_3-prelim-q4-results-upside-guidance\" target=\"_blank\">Ichor +8.3 on prelim Q4 results, upside guidance</a> (Jan. 17)</li><li>Related ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3323256\" data-linked=\"Semiconductor stocks moving after ASML, Ichor news\" data-tweet=\"$ASML $ASML $ICHR - Semiconductor stocks moving after ASML, Ichor news https://seekingalpha.com/news/3323256-semiconductor-stocks-moving-after-asml-ichor-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3323256-semiconductor-stocks-moving-after-asml-ichor-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323253\" data-ts=\"1516201307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHW\" target=\"_blank\">SCHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323253-schwab-down-1-after-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schwab down 1% after Q4 results</a></h4><ul><li>Q4 total revenue of $2.242B was up 14% Y/Y, thanks mostly to rising interest rates (net interest revenue up 26%). Trading revenue was down 24% Y/Y in Q4 thanks to big cuts in commissions (implemented about a year ago). For the year, trading revenue of $654M was down 21% from 2016.</li><li>1.4M new accounts opened last year, with households new to the retail business up 49% from 2016. $198.6B in core net new assets, up 58%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323209-charles-schwab-eps-line-beats-revenue\" target=\"_blank\">Charles Schwab EPS in-line, beats on revenue</a> (Jan. 17)</li><li>The Schwab (NYSE:<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a>) bulls today are taking a breather, with shares&nbsp;<font color='red'>down 1%</font>. They remain&nbsp;<font color='green'>higher by 8%</font>&nbsp;for 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323253\" data-linked=\"Schwab down 1% after Q4 results\" data-tweet=\"$SCHW - Schwab down 1% after Q4 results https://seekingalpha.com/news/3323253-schwab-down-1-after-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3323253-schwab-down-1-after-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323250\" data-ts=\"1516201104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICHR\" target=\"_blank\">ICHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323250-ichorplus-8_3-on-prelim-q4-results-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ichor +8.3 on prelim Q4 results, upside guidance</a></h4><ul><li>        Ichor (NASDAQ:<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a>) <a href=\"https://www.streetinsider.com/Corporate+News/Ichor+%28ICHR%29+Prelim.+Q4+Revenue+and+Q1+Outlook+Tops+Views/13692416.html\" target=\"_blank\">reports</a> preliminary Q4 results with $183M in revenue (consensus: $181M).</li><li>               About $4M of that revenue comes from the previously announced acquisition of Talon Innovations, which closed last month.&nbsp;</li><li>                  Cash and debt balances at year&rsquo;s end were $69M and $190M, respectively.    </li><li>               Q1 guidance has revenue from $240M to $250M (consensus: $208M) including $20M from the acquisition.&nbsp;</li><li>               Ichor will report Q4 earnings aftermarket on February 7.&nbsp;</li><li>               Ichor shares are&nbsp;<font color='green'>up 8.3%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3323250\" data-linked=\"Ichor +8.3 on prelim Q4 results, upside guidance\" data-tweet=\"$ICHR - Ichor +8.3 on prelim Q4 results, upside guidance https://seekingalpha.com/news/3323250-ichorplus-8_3-on-prelim-q4-results-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3323250-ichorplus-8_3-on-prelim-q4-results-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323249\" data-ts=\"1516201067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAGG\" target=\"_blank\">ZAGG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323249-b-riley-defense-lifts-zagg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">B. Riley defense lifts Zagg</a></h4><ul>     <li>B. Riley is out with a strong <a href=\"http://brileyfin.com/\" target=\"_blank\">defense</a> on Zagg (<a href='https://seekingalpha.com/symbol/ZAGG' title='ZAGG Inc'>ZAGG</a> <font color='green'>+8.4%</font>) as it doubles down on its Buy rating on the retailer.</li>     <li>The two-month drop in Zagg's share price is seen by the firm as unwarranted given Zagg's earnings potential this year on a strong product mix.</li>     <li>Shares of Zagg have ranged from $5.90 to $23.70 over the last 52 weeks. In early action today, they reached a high of $17.15.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323249\" data-linked=\"B. Riley defense lifts Zagg\" data-tweet=\"$ZAGG - B. Riley defense lifts Zagg https://seekingalpha.com/news/3323249-b-riley-defense-lifts-zagg?source=tweet\" data-url=\"https://seekingalpha.com/news/3323249-b-riley-defense-lifts-zagg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323246\" data-ts=\"1516201038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323246-late-stage-study-underway-evaluating-mimedxs-amniofix-in-achilles-tendonitis-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Late-stage study underway evaluating MiMedx&#39;s AmnioFix in Achilles tendonitis; shares up 1%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17049039-mimedx-announces-enrollment-first-patients-phase-3-clinical-trial-amniofix-injectable\" target=\"_blank\">Enrollment </a>has begun in a 158-subject Phase 3 clinical trial assessing MiMedx Group's (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='green'>+1.4%</font>) AmnioFix in patients with Achilles tendonitis. The primary endpoint is the change in Visual Analog Scale &#40;VAS&#41; score from baseline at day 90 compared to placebo.</li><li><a href=\"http://www.mimedx.com/products?qt-product_tabs=2#qt-product_tabs=&amp;quicktabs-product_tabs=1\" target=\"_blank\">AmnioFix&nbsp;</a>is a composite amniotic tissue membrane that is manipulated to protect the collagen matrix and its natural properties. The company says it acts a barrier, reduces scar tissue formation, enhances healing and modulates inflammation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323246\" data-linked=\"Late-stage study underway evaluating MiMedx&#39;s AmnioFix in Achilles tendonitis; shares up 1%\" data-tweet=\"$MDXG - Late-stage study underway evaluating MiMedx&#39;s AmnioFix in Achilles tendonitis; shares up 1% https://seekingalpha.com/news/3323246-late-stage-study-underway-evaluating-mimedxs-amniofix-in-achilles-tendonitis-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3323246-late-stage-study-underway-evaluating-mimedxs-amniofix-in-achilles-tendonitis-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323244\" data-ts=\"1516200228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOS\" target=\"_blank\">KTOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323244-kratos-announces-10_5m-defense-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kratos announces $10.5M defense contract</a></h4><ul><li>        Kratos Defense &amp; Security Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOS' title='Kratos Defense & Security Solutions, Inc.'>KTOS</a>) <a href=\"https://seekingalpha.com/pr/17048998-kratos-receives-10_5-million-task-order-modernize-cyberspace-defense-support-network\" target=\"_blank\">announces</a> a $10.5M task order from a Department of Defense Command.</li><li>                  The award involves modernizing expanding the cyberspace defense support network.    </li><li>                  Kratos shares are&nbsp;<font color='green'>up 1.1%.</font>&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3320830-kratos-receives-3_2m-drone-orders\" target=\"_blank\">Kratos receives $3.2M in drone orders</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323244\" data-linked=\"Kratos announces $10.5M defense contract\" data-tweet=\"$KTOS - Kratos announces $10.5M defense contract https://seekingalpha.com/news/3323244-kratos-announces-10_5m-defense-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3323244-kratos-announces-10_5m-defense-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323242\" data-ts=\"1516200188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323242-intrexon-prices-stock-offering-12_50-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon prices stock offering at $12.50; shares up 2%</a></h4><ul><li>Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='green'>+1.7%</font>) <a href=\"https://seekingalpha.com/pr/17049042-intrexon-prices-public-offering-common-stock\" target=\"_blank\">prices its public offering</a> of 6M shares of common stock at $12.50 per share. Underwriters over-allotment is an additional 900K shares. Closing date is January 19.</li><li>Yesterday's close was $13.77.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323242\" data-linked=\"Intrexon prices stock offering at $12.50; shares up 2%\" data-tweet=\"$XON - Intrexon prices stock offering at $12.50; shares up 2% https://seekingalpha.com/news/3323242-intrexon-prices-stock-offering-12_50-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3323242-intrexon-prices-stock-offering-12_50-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323237\" data-ts=\"1516199335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323237-grouponplus-1_8-goldman-takes-off-sell-sign\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon +1.8% as Goldman takes off Sell sign</a></h4><ul>   <li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) is <font color='green'>up 1.8%</font> premarket after a boost to Neutral from Sell at Goldman Sachs.</li>    <li>Most analysts are now Neutral on the stock with a handful scattered in Buy and Sell ratings.</li>    <li>Shares are <font color='green'>up 26%</font> over the past six months, and <font color='green'>up 40.5%</font> over the past 12.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323237\" data-linked=\"Groupon +1.8% as Goldman takes off Sell sign\" data-tweet=\"$GRPN - Groupon +1.8% as Goldman takes off Sell sign https://seekingalpha.com/news/3323237-grouponplus-1_8-goldman-takes-off-sell-sign?source=tweet\" data-url=\"https://seekingalpha.com/news/3323237-grouponplus-1_8-goldman-takes-off-sell-sign\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323236\" data-ts=\"1516199253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323236-macquarie-raises-qualcomm-price-target-on-broadcom-price-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macquarie raises Qualcomm price target on Broadcom, price cuts</a></h4><ul><li>        Macquarie <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Qualcomm+%28QCOM%29+PT+Raised+to+%2470+at+Macquarie%2C+higher+target+PER+due+to+AVGO+bid+%26+cost+cuts/13692088.html\" target=\"_blank\">raises</a> Qualcomm&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) price target from $55 to $70 citing the Broadcom takeover offer and cost cuts. The new target is about 3% above yesterday&rsquo;s closing price.</li><li>        Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=QCOM:NSQ\" target=\"_blank\">recommendations</a>: 5 Buy, 9 Outperform, and 13 Hold.</li><li>               Median price target: $65.&nbsp;</li><li>               Qualcomm shares are&nbsp;<font color='green'>up 0.7%</font>&nbsp;premarket to $68.70.&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322922-nomura-upgrades-qualcomm-calls-broadcom-takeover-attempt-gun-head\" target=\"_blank\">Nomura upgrades Qualcomm, calls Broadcom takeover attempt a \"gun to the head\"</a> (Jan. 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322960-qualcomm-promises-big-fy19-profits-shareholders-block-broadcom\" target=\"_blank\">Qualcomm promises big FY19 profits if shareholders block Broadcom</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323236\" data-linked=\"Macquarie raises Qualcomm price target on Broadcom, price cuts\" data-tweet=\"$QCOM - Macquarie raises Qualcomm price target on Broadcom, price cuts https://seekingalpha.com/news/3323236-macquarie-raises-qualcomm-price-target-on-broadcom-price-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3323236-macquarie-raises-qualcomm-price-target-on-broadcom-price-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323235\" data-ts=\"1516199248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323235-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+65%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3323176-neurometrix-inks-deal-glaxo-quell-ex-u-s-shares-ahead-68-percent-premarket\" target=\"_blank\">deal</a> with Glaxo for Quell ex-U.S.</li>     <li><a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+52%</font>&nbsp;on potential Juno <a href=\"https://seekingalpha.com/news/3323192-celgene-slips-2-percent-premarket-potential-juno-takeout\" target=\"_blank\">takeout</a>.</li>     <li><a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+24%&nbsp;</font>on&nbsp;<a href=\"https://seekingalpha.com/news/3323152-aeterna-zentaris-shares-halted-pending-news\" target=\"_blank\">agreement&nbsp;</a>with Strongbridge Biopharma plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a>) to commercialize Macrilen.</li>     <li><a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems Inc.'>MITK</a> <font color='green'>+12%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3309300-mitek-systems-beats-0_02-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+11%</font>&nbsp;on moving forward with its <a href=\"https://seekingalpha.com/pr/17048632-onconova-moving-forward-phase-3-inspire-pivotal-trial-increased-sample-size-following\" target=\"_blank\">Phase 3 INSPIRE</a> pivotal trial following the interim analysis, consistent with the DMC&rsquo;s recommendation.</li>     <li><a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+9%</font>&nbsp;on potential <a href=\"https://seekingalpha.com/news/3323181-juno-rally-spreads-car-t-developers\" target=\"_blank\">takeover</a> of CAR-T developers by Celgene</li>     <li><a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318122-stifel-names-top-wafer-fab-equipment-buys\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+7%</font>&nbsp;on potential Juno&nbsp;<a href=\"https://seekingalpha.com/news/3323192-celgene-slips-2-percent-premarket-potential-juno-takeout\" target=\"_blank\">takeout</a>.</li>     <li><a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a> <font color='green'>+6%</font>&nbsp;on purchase order <a href=\"https://seekingalpha.com/pr/17048875-jlm-energy-ideal-power-complete-750-kilowatt-purchase-order-ideal-power-s-stabiliti-series\" target=\"_blank\">agreement</a> with&nbsp;JLM Energy</li>     <li><a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a> <font color='green'>+6%&nbsp;</font>on Q3 <a href=\"https://seekingalpha.com/news/3323123-asml-holding-higher-5_7-percent-q4-profit-sales-beat\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='green'>+4%</font>&nbsp;on&nbsp;Virtual Surgical Planning <a href=\"https://seekingalpha.com/news/3323229-3d-systems-plus-6_4-percent-virtual-surgical-planning-partnership\" target=\"_blank\">partnership</a>.</li>     <li><a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323235\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$NURO $JUNO $AEZS - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3323235-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3323235-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323232\" data-ts=\"1516199062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323232-dish-network-cut-morgan-stanley-m-environment-dims\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish Network cut at Morgan Stanley as M&amp;A environment dims</a></h4><ul>   <li>Dish Network (NASDAQ:<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a>) is <font color='red'>0.9% lower</font> premarket after a cut to Equal Weight by Morgan Stanley, which sees dimming odds for a successful M&amp;A outcome for investors.</li>    <li>Possible buyer T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) has picked up more spectrum of its own, creating less need for the cache at Dish, says analyst Benjamin Swinburne; meanwhile, what might be the most logical buyer of the satellite assets -- AT&amp;T (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>) -- is mired in a government suit challenging its takeover of Time Warner. (h/t Bloomberg)</li>    <li>Liberty Global (NASDAQ:<a href='https://seekingalpha.com/symbol/LBTYA' title='Liberty Global, Inc.'>LBTYA</a>), though, is <font color='green'>up 1.7%</font> premarket as Swinburne boosts its rating to Overweight from Equal Weight on the promise of its new UK-focused build project.</li>    <li>Cable overall still may have its best days ahead, Swinburne says, with Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) and Charter (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) likely to reap benefits of tax reform and continuing broadband growth. <a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> is <font color='green'>up 1.1%</font> premarket; <a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a> is inactive.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3323232\" data-linked=\"Dish Network cut at Morgan Stanley as M&amp;A environment dims\" data-tweet=\"$DISH $DISH $TMUS - Dish Network cut at Morgan Stanley as M&amp;A environment dims https://seekingalpha.com/news/3323232-dish-network-cut-morgan-stanley-m-environment-dims?source=tweet\" data-url=\"https://seekingalpha.com/news/3323232-dish-network-cut-morgan-stanley-m-environment-dims\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323229\" data-ts=\"1516198597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323229-3d-systemsplus-6_4-on-virtual-surgical-planning-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D Systems +6.4% on Virtual Surgical Planning partnership</a></h4><ul><li>3D Systems (NYSE:<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a>) and Stryker (NYSE:<a href='https://seekingalpha.com/symbol/SYK' title='Stryker Corporation'>SYK</a>) <a href=\"https://www.streetinsider.com/Corporate+News/3D+Systems+%28DDD%29%2C+Stryker+%28SYK%29+Announce+Pact+to+Personalized+Surgery/13692854.html\" target=\"_blank\">announce</a> an exclusive distribution partnership for VSP (Virtual Surgical Planning) and craniomaxillofacial anatomical models.</li><li>3D established the VSP technology, which received FDA clearance in 2012 as a service-based personalized surgery approach combining medical imaging, surgical simulation, and 3D printing.</li><li>Stryker brings its specialized sales force to the partnership.</li><li>The agreement applies to the U.S., Canada, Europe, and Australia.</li><li>3D Systems shares are&nbsp;<font color='green'>up 6.4%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322178-idc-3d-printing-will-total-12b-2018\" target=\"_blank\">IDC: 3D printing will total $12B in 2018</a> (Jan. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323229\" data-linked=\"3D Systems +6.4% on Virtual Surgical Planning partnership\" data-tweet=\"$DDD $DDD $SYK - 3D Systems +6.4% on Virtual Surgical Planning partnership https://seekingalpha.com/news/3323229-3d-systemsplus-6_4-on-virtual-surgical-planning-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3323229-3d-systemsplus-6_4-on-virtual-surgical-planning-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323227\" data-ts=\"1516198474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323227-premarket-losers-of-9-05-1-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (1/17/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>&nbsp;<font color='red'>-25%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3323052-genocea-bio-initiates-equity-offering-shares-12-percent-hours\" target=\"_blank\">initiating</a> equity offering.</li><li><a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3323069-htg-molecular-readies-10m-share-stock-offering-shares-23-percent-hours\" target=\"_blank\">launching</a> public offering of 10M shares of common stock.</li><li><a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='red'>-15%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17048825-sequans-communications-s-announces-pricing-underwritten-public-offering-american-depositary\" target=\"_blank\">pricing</a> public offering of ADSs.</li><li><a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3323163-halozyme-16-percent-premarket-research-showing-incremental-treatment-benefit-pegph20\" target=\"_blank\">research</a> showing no incremental treatment benefit for PEGPH20 in pancreatic cancer.</li><li><a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-12%</font>.</li><li><a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3323091-boeing-adient-launch-jv-design-build-airplane-seats\" target=\"_blank\">announcing</a> joint venture with Boeing.</li><li><a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>&nbsp;<font color='red'>-6%</font>&nbsp;on Bitcoin <a href=\"https://seekingalpha.com/news/3323203-bitcoin-plunges-10k\" target=\"_blank\">plunging</a> below $10K.</li><li><a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3323227\" data-linked=\"Premarket Losers as of 9:05 am (1/17/2018)\" data-tweet=\"$GNCA $HTGM $SQNS - Premarket Losers as of 9:05 am (1/17/2018) https://seekingalpha.com/news/3323227-premarket-losers-of-9-05-1-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3323227-premarket-losers-of-9-05-1-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323225\" data-ts=\"1516198264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRS\" target=\"_blank\">VRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323225-verso-expands-strategic-alternatives-to-include-sale-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verso expands strategic alternatives to include sale or merger</a></h4><ul>     <li>Verso (NYSE:<a href='https://seekingalpha.com/symbol/VRS' title='Verso Corporation'>VRS</a>) <font color='green'>+9.7%</font> premarket after saying it has expanded its evaluation of potential transaction alternatives to include a <a href=\"https://seekingalpha.com/pr/17048145-verso-corporation-expands-strategic-alternatives-considerations\" target=\"_blank\">potential sale or merger</a> of the entire company.</li>     <li>VRS had previously formed a committee to identify and evaluate a range of potential strategic transaction alternatives to maximize shareholder value.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323225\" data-linked=\"Verso expands strategic alternatives to include sale or merger\" data-tweet=\"$VRS - Verso expands strategic alternatives to include sale or merger https://seekingalpha.com/news/3323225-verso-expands-strategic-alternatives-to-include-sale-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3323225-verso-expands-strategic-alternatives-to-include-sale-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323224\" data-ts=\"1516198201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNCA\" target=\"_blank\">GNCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323224-genocea-bio-prices-prices-equity-offering-1-shares-down-21-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genocea Bio prices prices equity offering at $1; shares down 21% premarket</a></h4><ul><li>Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) slumps&nbsp;<font color='red'>21%</font>&nbsp;premarket on average volume in response to the <a href=\"https://seekingalpha.com/pr/17048900-genocea-biosciences-inc-announces-pricing-55-million-concurrent-public-offerings\" target=\"_blank\">pricing </a>of its equity offering.</li><li>It will offer ~53.4M shares of common stock and accompanying Class A warrants to purchase up to ~26.7M shares of common at a combined price of $1 (each five-year Class A warrant can purchase 1/2 of a share of stock at $1.20).</li><li>Underwriters over-allotment is an additional ~8M shares of stock and Class A warrants. Closing date is January 19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323224\" data-linked=\"Genocea Bio prices prices equity offering at $1; shares down 21% premarket\" data-tweet=\"$GNCA - Genocea Bio prices prices equity offering at $1; shares down 21% premarket https://seekingalpha.com/news/3323224-genocea-bio-prices-prices-equity-offering-1-shares-down-21-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3323224-genocea-bio-prices-prices-equity-offering-1-shares-down-21-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323208\" data-ts=\"1516196716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTG\" target=\"_blank\">PSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323208-barclays-upgrades-pure-storage-36-upside-sharesplus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays upgrades Pure Storage with 36% upside; shares +3%</a></h4><ul><li>        Barclays <a href=\"https://www.streetinsider.com/Analyst+Comments/Barclays+Upgrades+Pure+Storage+%28PSTG%29+to+Overweight/13691484.html\" target=\"_blank\">upgrades</a> Pure Storage (NYSE:<a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a>) from Equal Weight to Overweight and raises the price target by $3 to $22, which is 36% higher than yesterday&rsquo;s closing price.</li><li>               Analyst Mark Moskowitz sees an opportunity for Pure Storage to &ldquo;pitch its brand&rdquo; and achieve a higher market share as other legacy hardware vendors experience strategy struggles.&nbsp;</li><li>               Pure Storage shares are&nbsp;<font color='green'>up 3.1%</font>&nbsp;premarket to $16.65.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3323208\" data-linked=\"Barclays upgrades Pure Storage with 36% upside; shares +3%\" data-tweet=\"$PSTG - Barclays upgrades Pure Storage with 36% upside; shares +3% https://seekingalpha.com/news/3323208-barclays-upgrades-pure-storage-36-upside-sharesplus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3323208-barclays-upgrades-pure-storage-36-upside-sharesplus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323202\" data-ts=\"1516196354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323202-biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx announces partial monotherapy results from Phase 2a COMBAT study in pancreatic cancer</a></h4><ul><li>BioLineRx&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a>) <a href=\"https://seekingalpha.com/pr/17048582-biolinerx-announces-partial-monotherapy-results-phase-2a-combat-study-pancreatic-cancer\" target=\"_blank\">announces</a> partial results from the monotherapy portion of <a href=\"http://www.biolinerx.com/default.asp?pageid=98&amp;itemid=41\" target=\"_blank\">BL-8040</a>'s Phase 2a COMBAT study showing that BL-8040 increases infiltration of T cells into the tumor in patients with metastatic pancreatic cancer.</li><li>The data will be presented&nbsp;at the ASCO 2018 Gastrointestinal Cancers Symposium, on January 19 in San Francisco, CA.</li> <li>The partial results shows that BL-8040 was safe and well-tolerated. The results showed up to a 15-fold increase in CD3+ T cells, and up to a 2-fold increase in CD8+ T cells, in the TME of 43% (3/7) of the patients, after five days of BL-8040 monotherapy.</li> <li>Topline results of the study are expected by H2 2018.</li>   <li>BL-8040 is a short peptide for the treatment of acute myeloid leukemia, solid tumors, and stem cell mobilization.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323202\" data-linked=\"BioLineRx announces partial monotherapy results from Phase 2a COMBAT study in pancreatic cancer\" data-tweet=\"$BLRX - BioLineRx announces partial monotherapy results from Phase 2a COMBAT study in pancreatic cancer https://seekingalpha.com/news/3323202-biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic?source=tweet\" data-url=\"https://seekingalpha.com/news/3323202-biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323203\" data-ts=\"1516196287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323203-bitcoin-plunges-below-10k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin plunges below $10K</a></h4><ul><li>The price has recovered to $10.2K at the moment, but Bitcoin earlier this morning was back in four-figure territory as the broad selloff in cryptos deepens.</li><li><a href=\"https://www.bloomberg.com/news/articles/2018-01-17/did-bitcoin-just-burst-how-it-compares-to-history-s-big-bubbles\" target=\"_blank\">Most in traditional media</a> and asset management are congratulating themselves for spotting and avoiding a bubble of massive proportions, but to cryptocurrency veterans, this plunge is nothing out of the ordinary. Who's correct remains in the cards.</li><li>Ethereum - which soared to news highs this year even as Bitcoin was languishing - has been hit particularly hard this week. It's&nbsp;<font color='red'>down 16%</font>&nbsp;today to $878, and&nbsp;<font color='red'>about 40%</font>&nbsp;since topping $1,400 over the weekend.</li><li>Ripple is&nbsp;<font color='red'>down another 10%</font>&nbsp;to $1.04, now&nbsp;<font color='red'>off more than 70%</font>&nbsp;in the past 12 days.</li><li><a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>&nbsp;<font color='red'>-7.2%</font>&nbsp;premarket</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/BTLLF' title='Interbit Ltd.'>OTCPK:BTLLF</a> <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/UBIA' title='UBI BlockChain Internet Ltd.'>OTC:UBIA</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/CRCW' title='The Crypto Company'>OTC:CRCW</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3323203\" data-linked=\"Bitcoin plunges below $10K\" data-tweet=\"$GBTC $GBTC $COIN - Bitcoin plunges below $10K https://seekingalpha.com/news/3323203-bitcoin-plunges-below-10k?source=tweet\" data-url=\"https://seekingalpha.com/news/3323203-bitcoin-plunges-below-10k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>240&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323201\" data-ts=\"1516196245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323201-barclays-gives-ibm-double-upgrade-on-cloud-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays gives IBM a double upgrade on cloud potential</a></h4><ul><li>        Barclays <a href=\"http://www.nasdaq.com/article/ibm-shares-rise-after-barclays-double-upgrade-20180117-00449\" target=\"_blank\">upgrades</a> IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) from Underweight to Overweight and raises the price target from $133 to $192, which is 17% above yesterday&rsquo;s closing price.</li><li>               Analyst Mark Moskowitz says IBM could become the next major cloud vendor alongside Amazon Web Services and Microsoft Azure.&nbsp;</li><li>                  Potential tailwind: The Spectre and Meltdown chip security flaws could help IBM gain market share in the mid-range and high-end server market.    </li><li>               The analyst thinks IBM&rsquo;s revenue could stabilize or grow in the next 12 to 18 months.&nbsp;</li><li>               IBM reports Q4 results aftermarket on Thursday. Revenues have dropped for the past 22 quarters.&nbsp;</li><li>               IBM shares are&nbsp;<font color='green'>up 1.8%</font>&nbsp;premarket to $166.74.&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322874-ibm-maersk-launch-blockchain-platform-tracking-cargo\" target=\"_blank\">IBM, Maersk launch blockchain platform for tracking cargo</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3323201\" data-linked=\"Barclays gives IBM a double upgrade on cloud potential\" data-tweet=\"$IBM - Barclays gives IBM a double upgrade on cloud potential https://seekingalpha.com/news/3323201-barclays-gives-ibm-double-upgrade-on-cloud-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3323201-barclays-gives-ibm-double-upgrade-on-cloud-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323199\" data-ts=\"1516195911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAT\" target=\"_blank\">TAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323199-transatlantic-petroleum-hires-advisor-to-market-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransAtlantic Petroleum hires advisor to market the company</a></h4><ul>     <li>TransAtlantic Petroleum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TAT' title='TransAtlantic Petroleum Ltd.'>TAT</a>)&nbsp;<font color='green'>+5.7%</font> premarket after saying it formed a strategic committee and has hired Tudor Pickering Holt as a financial advisor to market the company and <a href=\"https://seekingalpha.com/pr/17048311-transatlantic-petroleum-announces-engagement-financial-advisor-market-company-provides\" target=\"_blank\">explore strategic alternatives</a>.</li>     <li>Also, TAT says it has launched a new drilling program in Turkey and estimates rig mobilization will be completed and a new well will spud in the first week of February.</li>     <li>TAT also is continuing to evaluate its prospects in the Thrace Basin in Turkey following recent positive production test results at a nearby exploration well  operated by Valeura and partner Statoil.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3323199\" data-linked=\"TransAtlantic Petroleum hires advisor to market the company\" data-tweet=\"$TAT - TransAtlantic Petroleum hires advisor to market the company https://seekingalpha.com/news/3323199-transatlantic-petroleum-hires-advisor-to-market-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3323199-transatlantic-petroleum-hires-advisor-to-market-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3323192\" data-ts=\"1516194957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELG\" target=\"_blank\">CELG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3323192-celgene-slips-2-premarket-on-potential-juno-takeout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celgene slips 2% premarket on potential Juno takeout</a></h4><ul><li>Investors appear to be have a neutral view on Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) (<font color='red'>-2%</font>&nbsp;premarket) if it, indeed, follows through and acquires collaboration partner Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) (<font color='green'>+56%</font>&nbsp;premarket).</li><li>Mizuho Securities says Celgene already has a decent partnership with Juno and, arguably, does not need the deal, especially since accretion won't happen until 2021/22.</li><li>On the plus side, it believes a tie-up makes good strategic sense and removes/simplifies the firewall between CELG employees working with JUNO and bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>).</li><li>Leerink's Geoffrey Porges <a href=\"https://endpts.com/wsj-juno-shares-rocket-higher-on-word-that-celgene-is-hunting-a-buyout-deal/\" target=\"_blank\">believes </a>Juno won't accept an offer valued below $11.9B that Gilead paid for Kite Pharma, adding that Celgene paid $93/share to acquire its initial stake of ~9.1M shares in 2015.</li><li>Citigroup sees a $110/share valuation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3323192\" data-linked=\"Celgene slips 2% premarket on potential Juno takeout\" data-tweet=\"$CELG $CELG $JUNO - Celgene slips 2% premarket on potential Juno takeout https://seekingalpha.com/news/3323192-celgene-slips-2-premarket-on-potential-juno-takeout?source=tweet\" data-url=\"https://seekingalpha.com/news/3323192-celgene-slips-2-premarket-on-potential-juno-takeout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}